<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Management of complications in patients with Fontan circulation</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Management of complications in patients with Fontan circulation</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Management of complications in patients with Fontan circulation</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jonathan Johnson, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Heidi M Connolly, MD, FACC, FASE</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Gruschen Veldtman, MBChB, FRCP, Dip Obst</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Susan B Yeon, MD, JD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Feb 23, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H13723552"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The Fontan operation is a palliative surgical procedure performed in patients with a functional or anatomic single ventricle (also known as univentricular heart) [<a href="#rid1">1,2</a>]. The Fontan operation was originally described for patients with tricuspid atresia by Fontan [<a href="#rid3">3</a>] and by Kreutzer [<a href="#rid4">4</a>] in 1971. In the past 50 years, the types of malformations for which the Fontan operation is utilized has expanded considerably, and it has become the most common operation performed for patients with any type of single ventricle [<a href="#rid5">5</a>]. Patients face substantial morbidity and mortality risks after Fontan palliation and require lifelong follow-up with a cardiologist experienced in the care of patients with complex congenital heart disease (eg, pediatric cardiologist or adult congenital heart disease specialist).</p><p>This topic will discuss management and prevention of complications in patients who have undergone Fontan procedures. An overview of the management of patients post-Fontan procedure is presented separately. (See  <a class="medical medical_review" href="/z/d/html/122375.html" rel="external">"Overview of the management and prognosis of patients with Fontan circulation"</a>.)</p><p class="headingAnchor" id="H1303197149"><span class="h1">INDICATIONS FOR REINTERVENTION</span><span class="headingEndMark"> — </span>During long-term follow-up, Fontan survivors commonly require catheter-based or surgical reintervention. Catheter-based interventions may include fenestration closure or creation, Fontan connection dilation/stenting, and pulmonary artery intervention. Surgical reinterventions include conversion surgery and reoperation to address complications.</p><p>Mechanical circulatory support and heart transplantation to treat advanced heart failure are discussed below. (See <a class="local">'Management of advanced heart failure'</a> below.)</p><p>In a series of 773 patients who underwent Fontan procedure, freedom from reoperation was 69 percent at 15 years and 63 percent at 20 years; the most common operations were permanent pacemaker placement and Fontan revision [<a href="#rid6">6</a>]. Freedom from catheter-based intervention was 53 percent at 15 years and 50 percent at 20 years.</p><p class="headingAnchor" id="H1642527555"><span class="h2">Fontan conversion surgery</span><span class="headingEndMark"> — </span>In selected patients with a history of atriopulmonary Fontan circulation, surgical total cavopulmonary conversion to an extracardiac conduit (or intracardiac lateral tunnel or intraatrial conduit) is considered [<a href="#rid1">1,2,7,8</a>].</p><p>The following are indications for evaluating the benefits and risks of Fontan conversion, which should be performed at centers with experience with these high-risk procedures:</p><p class="bulletIndent1"><span class="glyph">●</span>Symptomatic refractory arrhythmias (eg, intraatrial reentry tachycardia, atrial fibrillation, or flutter). (See <a class="local">'Arrhythmias'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Right atrial thrombosis. (See <a class="local">'Thrombosis'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Fontan pathway obstruction not amenable to transcatheter intervention.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Exercise intolerance.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pulmonary venous compression (particularly the right-sided pulmonary veins) by a very dilated right atrium in an old atriopulmonary connection Fontan.</p><p></p><p>In patients who present with symptomatic arrhythmias,<strong> </strong>total cavopulmonary<strong> </strong>conversion in conjunction with arrhythmia surgery (Maze procedure) has been shown to reduce the arrhythmia burden and improve exercise tolerance [<a href="#rid9">9,10</a>]. (See  <a class="medical medical_review" href="/z/d/html/1046.html" rel="external">"Atrial fibrillation: Surgical ablation"</a>.)</p><p class="headingAnchor" id="H3525191878"><span class="h2">Other reoperations</span><span class="headingEndMark"> — </span>Other indications for reoperation after Fontan procedure include the following [<a href="#rid1">1,2</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Residual atrial septal defect or other intracardiac shunt, resulting in symptomatic right-to-left shunt (with or without cyanosis) not amenable to transcatheter closure. (See <a class="local">'Cyanosis and shunts'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hemodynamically significant residual systemic-artery-to-pulmonary-artery shunt, residual surgical shunt, or residual ventricle-to-pulmonary-artery connection not amenable to transcatheter closure.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Severe systemic atrioventricular (AV) valve regurgitation with symptoms, progressive ventricular dilation, or ventricular dysfunction. (See <a class="local">'Atrioventricular valve regurgitation'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Subaortic obstruction with peak-to-peak gradient greater than 30 mmHg.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Fontan pathway obstruction.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Venous collateral channels or pulmonary arteriovenous malformation not amenable to transcatheter management. (See <a class="local">'Cyanosis and shunts'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pulmonary venous obstruction.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Aortic arch obstruction.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Rhythm abnormalities such as complete heart block, requiring epicardial pacemaker/defibrillator insertion. (See <a class="local">'Arrhythmias'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Indication for fenestration creation or closure not amenable to transcatheter intervention. (See  <a class="medical medical_review" href="/z/d/html/122375.html" rel="external">"Overview of the management and prognosis of patients with Fontan circulation", section on 'Fenestration'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Residual obstruction across atrial septum in hypoplastic left or right heart lesions in the presence of total cavopulmonary connection.</p><p></p><p class="headingAnchor" id="H13723654"><span class="h1">CARDIOVASCULAR COMPLICATIONS</span></p><p class="headingAnchor" id="H108728384"><span class="h2">Cyanosis and shunts</span><span class="headingEndMark"> — </span>Patients with Fontan circulation generally have mild systemic arterial oxygen desaturation (oxygen saturation is most commonly 90 to 95 percent), but some patients have more marked oxygen desaturation [<a href="#rid1">1</a>]. Cyanosis in Fontan patients can be caused by persistent drainage of the coronary sinus into the systemic atrium and ventilation-perfusion mismatch; patients can also have right-to-left shunting via fenestrations or other intra- or extracardiac communications [<a href="#rid11">11</a>]. (See  <a class="medical medical_review" href="/z/d/html/122375.html" rel="external">"Overview of the management and prognosis of patients with Fontan circulation", section on 'Fontan "physiology"'</a>.)</p><p>Cyanotic Fontan patients (with oxygen saturation &lt;90 percent at rest) who have not received intentional fenestration should undergo cardiac catheterization by a congenital cardiologist, including a search for systemic-venous-to-pulmonary-venous connection via venous collateral decompression, inadvertent fenestration, pulmonary arteriovenous malformations (PAVMs), Fontan circuit obstruction, and other potential right-to-left shunts (eg, atrial shunt; or inferior vena cava [IVC], superior vena cava [SVC], or innominate-vein-to-left atrial shunt) [<a href="#rid1">1</a>]. The development of PAVMs has been attributed to one or more hepatic factors not reaching the pulmonary vascular bed. Shunting of hepatic venous flow away from one lung (as seen in some forms of heterotaxy syndrome) can lead to development of PAVMs in the lung not receiving hepatic venous effluent, and reestablishing hepatic venous flow to an affected lung can lead to improvement or resolution of PAVMs [<a href="#rid1">1</a>]. Obstruction can occur anywhere in the circuit (eg, IVC-to-pulmonary-artery conduit obstruction, branch pulmonary artery obstruction, or SVC/Glenn obstruction) and should be evaluated by advanced imaging (eg, computed tomography [CT], cardiovascular magnetic resonance imaging [CMR], or catheterization) in any cyanotic Fontan patient since it can be missed by echo-Doppler evaluation.</p><p>Venovenous collaterals (arising from the systemic venous vessels and draining to the pulmonary venous vessels) are among the potential causes of decreasing oxygen saturation following Fontan operation. Venovenous collaterals are seen in 20 to 45 percent of patients undergoing catheterization after Fontan or Glenn operations [<a href="#rid12">12,13</a>]. These collaterals are thought to occur due to the chronically elevated central venous pressure either at rest or during exertion.<strong> </strong>The collaterals act as a de facto right-to-left shunt, causing systemic desaturation and also posing a risk for paradoxical embolism. In the absence of cyanosis or symptoms, no treatment or surveillance for venovenous collaterals are required.</p><p>The presence of worsening systemic desaturation at rest or with exercise, or a history of an event attributable to the paradoxical shunt associated with the venovenous collaterals, are considered reasonable indications to proceed with collateral evaluation and potential occlusion. Comprehensive review and discussion are indicated prior to intervention for shunts; the benefits of closing (or altering) communications to improve oxygen saturation should be weighed against the potential risks of increased impedance to venous return, decreased cardiac output, and fall in oxygen delivery [<a href="#rid1">1</a>]. Limited data exist to guide decisions about whether to close a particular collateral vessel in the congenital cardiac catheterization laboratory [<a href="#rid14">14</a>]. In patients without intentional fenestration, persistent clinically significant venous collateral channels and other right-to-left shunts can be treated with transcatheter occlusion but often reoccur after intervention. However, venovenous fistula closure may adversely impact survival, particularly in patients with atriopulmonary-type Fontan, heterotaxy, or Fontan pressure above 18 mmHg, so the potential risks and benefits should be carefully weighed [<a href="#rid14">14</a>]. Reoperation may be necessary to close an unintended residual atrial septal defect that results in cyanosis and is not amenable to transcatheter closure [<a href="#rid2">2</a>]. (See <a class="local">'Other reoperations'</a> above.)</p><p>If cyanosis cannot be corrected (or is accepted in a patient with intentional fenestration), standard management for patients with cyanotic heart disease should be instituted (such as meticulous intravenous line care) to avoid air embolism. (See  <a class="medical medical_review" href="/z/d/html/1423.html" rel="external">"Medical management of cyanotic congenital heart disease in adults"</a>.)</p><p>Systemic anticoagulation therapy is recommended for all Fontan patients with cyanosis (with oxygen saturation &lt;90 percent at rest) related to fenestration or collateral formation due to the risk of paradoxical systemic thromboembolism in this setting if benefits outweigh risks.</p><p>Due to limited data on direct oral anticoagulants, vitamin K antagonist is currently preferred in this patient population. (See <a class="local">'Thrombosis'</a> below.)</p><p class="headingAnchor" id="H552744857"><span class="h2">Arrhythmias</span><span class="headingEndMark"> — </span>By 10 years after Fontan operation, more than 20 percent of patients have supraventricular tachyarrhythmia, and arrhythmias occur in over 50 percent of patients with prior atriopulmonary Fontan procedure [<a href="#rid15">15</a>]. The incidence of atrial tachycardia appears to be significantly lower after total cavopulmonary connection (eg, lateral tunnel Fontan or extracardiac conduit Fontan), compared with the older atriopulmonary connection Fontan [<a href="#rid16">16</a>]. Intraatrial reentry tachycardia and atrial flutter are the most common arrhythmias following atriopulmonary Fontan procedure [<a href="#rid17">17</a>]. Sinus node dysfunction is also commonly observed in patients with Fontan circulation and may result in impaired heart rate response to exercise.</p><p>Patients with arrhythmias following Fontan operation may present with palpitations, hemodynamic deterioration, nonspecific functional decline, embolic events, and occasionally they may be asymptomatic. Atrial arrhythmia episodes, including intraatrial reentry tachycardia, can cause hemodynamic compromise and clot formation.</p><p>Consultation with an experienced congenital heart disease electrophysiologist and prompt appropriate management are recommended for patients with atrial or ventricular arrhythmias following Fontan operation, given the risk of significant morbidity [<a href="#rid1">1,2</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>New atrial arrhythmias in a patient with prior Fontan procedure warrant comprehensive assessment for an underlying cause such as electrolyte disorder, thyroid disorder, sleep apnea, or a structural problem such as Fontan obstruction or ventricular or valve dysfunction. Secondary complications such as intracardiac thrombus and heart failure should be identified and treated.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Systemic anticoagulation is recommended for all Fontan patients with atrial arrhythmias [<a href="#rid2">2,18</a>]. Due to limited data on direct oral anticoagulants, vitamin K antagonist (eg, <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a>) is currently the preferred therapy. (See <a class="local">'Thrombosis'</a> below.)</p><p></p><p>Sustained arrhythmia associated with hemodynamic compromise is a medical emergency; electrical cardioversion is the treatment of choice and is usually effective. Transesophageal echocardiography is generally recommended for all Fontan patients undergoing elective cardioversion for atrial arrhythmias, even when on anticoagulation, due to a high risk of atrial thrombus. The most common sites for thrombus are right atrium, Fontan conduit, left atrial appendage, and pulmonary vein orifices.</p><p>Patients with infrequent (less than once per year), promptly recognized, and well-tolerated intraatrial tachycardia may be treated with a chronic AV-node-blocking agent (eg, <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">digoxin</a>, beta blocker, or calcium channel blocker) to limit the rate of ventricular response, anticoagulation, and periodic cardioversion. If episodes of intraatrial tachycardia are frequent, symptomatic, not promptly recognized by the patient, or are associated with atrial thrombus formation, treatment to prevent recurrences is indicated.</p><p>Treatment to prevent recurrent atrial arrhythmias, including intraatrial reentry tachycardia, is a major challenge and includes the following options:</p><p class="bulletIndent1"><span class="glyph">●</span>Class III antiarrhythmic agents (eg, <a class="drug drug_general" data-topicid="9941" href="/z/d/drug information/9941.html" rel="external">sotalol</a> and <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">amiodarone</a>) are used to treat symptomatic atrial flutter not related to Fontan obstruction. These agents should be started in the hospital under cardiovascular monitoring.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Catheter ablation is used as an adjunctive strategy or first-line strategy in young patients who prefer to avoid lifelong antiarrhythmic therapy [<a href="#rid19">19</a>]. This procedure should be performed at a specialized center by an electrophysiologist experienced with the management of patients with complex congenital heart disease and prior Fontan procedure. (See  <a class="medical medical_review" href="/z/d/html/949.html" rel="external">"Atrial fibrillation: Catheter ablation"</a> and  <a class="medical medical_review" href="/z/d/html/1048.html" rel="external">"Overview of atrial flutter"</a> and  <a class="medical medical_review" href="/z/d/html/1007.html" rel="external">"Overview of catheter ablation of cardiac arrhythmias"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Customized pacemaker (eg, antibradycardia or antitachycardia) therapy has been suggested as a means of improving arrhythmia management in patients following Fontan operation. Dual-chamber epicardial antitachycardia pacemakers are often used after Fontan conversion [<a href="#rid20">20</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Surgical conversion to a total cavopulmonary connection with arrhythmia surgery is suggested for select patients with features of Fontan obstruction not amendable to other treatments or refractory arrhythmias despite medical- or catheter-based therapy  (<a class="graphic graphic_figure graphicRef95320" href="/z/d/graphic/95320.html" rel="external">figure 1</a>).</p><p></p><p>Serial exercise testing may identify impaired heart rate response, which may require treatment with an atrial rate responsive pacemaker in selected patients [<a href="#rid1">1</a>]. When a permanent pacemaker is indicated, AV synchrony should be preserved when feasible, since ventricular pacing may negatively affect cardiac output and quality of life [<a href="#rid1">1</a>].</p><p>Standard indications for implantable cardioverter-defibrillator apply to patients with Fontan circulation. Data are lacking on the use of epicardial or subcutaneous implantable cardioverter-defibrillator placement for primary prevention in patients with Fontan circulation. (See  <a class="medical medical_review" href="/z/d/html/91077.html" rel="external">"Primary prevention of sudden cardiac death in patients with cardiomyopathy and heart failure with reduced LVEF"</a> and  <a class="medical medical_review" href="/z/d/html/946.html" rel="external">"Secondary prevention of sudden cardiac death in heart failure and cardiomyopathy"</a>.)</p><p class="headingAnchor" id="H13723670"><span class="h2">Heart failure</span><span class="headingEndMark"> — </span>Heart failure is defined as a common clinical syndrome with symptoms caused by impaired ability of one or both ventricles to meet resting and exercise demands at a normal pressure due to a structural or functional cardiac disorder. Given this definition, all patients with Fontan circulation have chronic heart failure with elevated systemic venous pressure and low cardiac output. Additional conditions that contribute to heart failure in some Fontan patients include systemic ventricular systolic and/or diastolic dysfunction, AV valve regurgitation, rhythm disorders, volume-loading shunts, Fontan obstruction, and pericardial restraint/constriction. (See <a class="local">'Atrioventricular valve regurgitation'</a> below and <a class="local">'Arrhythmias'</a> above and <a class="local">'Other reoperations'</a> above.)</p><p>Symptoms and signs of heart failure in Fontan patients include fatigue, dyspnea, central nervous system symptoms similar to superior vena cava syndrome, end-organ dysfunction (eg, renal insufficiency and liver dysfunction),<strong> </strong>edema, and ascites.</p><p class="headingAnchor" id="H1579784315"><span class="h3">General management</span><span class="headingEndMark"> — </span>The management of heart failure in Fontan patients includes medical therapy for heart failure, selective use of biventricular pacing, and selective use of pulmonary vasodilator therapy.</p><p>The approach to management of heart failure is similar to that for non-Fontan patients but requires caution given the risk of precipitating a low-output state. Diuretics to treat volume overload should be used with caution since diuresis may decrease edema but can exacerbate low-output symptoms by decreasing systemic venous pressure.</p><p class="bulletIndent1"><span class="glyph">●</span>Some experts treat Fontan patients with heart failure with reduced ejection fraction (HFrEF; left ventricular ejection fraction [LVEF] ≤40 percent) or asymptomatic ventricular dysfunction (LVEF ≤40 percent) with a renin-angiotensin system inhibitor (eg, angiotensin converting enzyme [ACE] inhibitor or angiotensin II receptor blocker [ARB]) or angiotensin receptor-neprilysin inhibitor. Use of renin-angiotensin inhibitor therapy in this setting is based upon indirect evidence in non-Fontan patients with HFrEF or asymptomatic left ventricular systolic dysfunction, as there is scant evidence in Fontan patients [<a href="#rid21">21</a>]. (See  <a class="medical medical_review" href="/z/d/html/121086.html" rel="external">"Primary pharmacologic therapy for heart failure with reduced ejection fraction"</a> and  <a class="medical medical_review" href="/z/d/html/3509.html" rel="external">"Management and prognosis of asymptomatic left ventricular systolic dysfunction"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Similarly, selected beta blockers (eg, <a class="drug drug_general" data-topicid="9645" href="/z/d/drug information/9645.html" rel="external">metoprolol</a> succinate, <a class="drug drug_general" data-topicid="9208" href="/z/d/drug information/9208.html" rel="external">carvedilol</a>, or <a class="drug drug_general" data-topicid="9158" href="/z/d/drug information/9158.html" rel="external">bisoprolol</a>, the beta blockers with established benefit for HFrEF generally) (see  <a class="medical medical_review" href="/z/d/html/121086.html" rel="external">"Primary pharmacologic therapy for heart failure with reduced ejection fraction"</a>) are used with caution in select Fontan patients with HFrEF or asymptomatic ventricular dysfunction. Use of beta blockers in this setting is based on indirect evidence in non-Fontan patients. Beta blocker use to treat atrial arrhythmias is discussed above (see <a class="local">'Arrhythmias'</a> above). Monitoring of chronotropic competence is important when beta blockers are used in this population. Negative inotropic drugs are otherwise generally avoided in patients with single-ventricle dysfunction.</p><p></p><p>Biventricular pacing is an option for selected patients with persistent low output despite optimized medical therapy [<a href="#rid22">22-24</a>]. This device should be placed by an experienced congenital electrophysiologist with knowledge of the anatomic challenges. (See  <a class="medical medical_review" href="/z/d/html/3475.html" rel="external">"Cardiac resynchronization therapy in heart failure: Indications and choice of system"</a>.)</p><p class="headingAnchor" id="H1929230110"><span class="h3">Pulmonary vasodilator therapy</span><span class="headingEndMark"> — </span>For Fontan patients with high indexed pulmonary vascular resistance (PVRI; &gt;2 Wood units x m<sup>2</sup>), we suggest pulmonary vasodilator therapy. This is an area of ongoing investigation, as there are limited data to support this approach. An observational study identified the combination of high PVRI and low cardiac index (defined as &lt;2.5 L/minutes/m<sup>2</sup>) as an independent risk factor for Fontan failure (defined as all-cause mortality, listing for heart transplantation, or initiation of palliative care; hazard ratio [HR] 1.84, 95% CI 1.09-2.85) [<a href="#rid25">25</a>]. Agents commonly used in Fontan patients with elevated PVRI include an endothelin receptor antagonist (ERA; eg, <a class="drug drug_general" data-topicid="9254" href="/z/d/drug information/9254.html" rel="external">bosentan</a>) or a phosphodiesterase type 5 inhibitor (eg, <a class="drug drug_general" data-topicid="9643" href="/z/d/drug information/9643.html" rel="external">sildenafil</a>). Calcium channel blockers are generally not tolerated in this setting and are generally avoided.</p><p class="bulletIndent1"><span class="glyph">●</span>Support for use of an ERA in this setting comes from the TEMPO trial in which 75 adolescents and adults were randomly assigned to 14 weeks of treatment with <a class="drug drug_general" data-topicid="9254" href="/z/d/drug information/9254.html" rel="external">bosentan</a> or placebo [<a href="#rid26">26</a>]. There were greater improvements in New York Heart Association (NYHA) functional class (nine improved in the bosentan group versus none in the placebo group), peak oxygen consumption, and cardiopulmonary exercise test time in the bosentan group. Side effects were mild and generally similar in the two groups.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In an uncontrolled study of eight children, eight adolescents, and eight adults with Fontan circulation with PVRI ≥2 Wood units x m<sup>2</sup> and treated with an ERA (<a class="drug drug_general" data-topicid="9254" href="/z/d/drug information/9254.html" rel="external">bosentan</a> in minors, <a class="drug drug_general" data-topicid="91206" href="/z/d/drug information/91206.html" rel="external">macitentan</a> in adults) for six months, declines in PVR were observed in all three age groups, and increases in cardiac output were observed in adolescents and adults [<a href="#rid27">27</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Use of phosphodiesterase type 5 inhibitor in this setting is supported by a randomized crossover trial in 28 patients with Fontan circulation in which <a class="drug drug_general" data-topicid="9643" href="/z/d/drug information/9643.html" rel="external">sildenafil</a> (20 mg three times daily for six weeks) improved ventilatory efficiency compared with placebo [<a href="#rid28">28</a>]. Flushing was more frequent with sildenafil (5 of 27 versus 0 of 28 patients). A small study has reported on the use of <a class="drug drug_general" data-topicid="10108" href="/z/d/drug information/10108.html" rel="external">tadalafil</a> in patients with Fontan circulation as well [<a href="#rid29">29</a>].</p><p></p><p class="headingAnchor" id="H785619090"><span class="h3">Management of advanced heart failure</span><span class="headingEndMark"> — </span>Limited options are available for the complex Fontan patient with end-stage heart failure. Mechanical circulatory support with a ventricular assist device and/or cardiac transplantation is considered in patients following Fontan operation who have refractory low-output symptoms despite optimized medical and device therapy as a bridge to transplantation [<a href="#rid30">30,31</a>]. (See  <a class="medical medical_review" href="/z/d/html/3459.html" rel="external">"Treatment of advanced heart failure with a durable mechanical circulatory support device"</a> and  <a class="medical medical_review" href="/z/d/html/87834.html" rel="external">"Management of long-term mechanical circulatory support devices"</a>.)</p><p>Early experiences with outpatient ventricular assist device use in patients post-Fontan were limited to small case series at single centers [<a href="#rid30">30,32,33</a>] (see  <a class="medical medical_review" href="/z/d/html/3459.html" rel="external">"Treatment of advanced heart failure with a durable mechanical circulatory support device"</a>). In a report from the ACTION network of 45 Fontan patients supported by ventricular assist devices, at one year after device implantation, 70 percent of patients had been successfully transplanted, while 21 percent of patients had died [<a href="#rid34">34</a>]. Adverse events were common and occurred in 67 percent of patients, with neurologic events the most common type of adverse event.</p><p>Although medical issues in Fontan patients complicate and/or preclude isolated cardiac transplantation in some cases, it remains an option for many patients.<strong> </strong>Factors limiting isolated heart transplant candidacy include severe hepatic dysfunction (including cirrhosis and risk of hepatocellular carcinoma), chronic kidney disease, pulmonary insufficiency (including single functional lung), infection risk (particularly in patients with protein-losing enteropathy [PLE] and asplenia), and presensitization. Heart-liver transplant is a treatment option for some patients. Due to multiple prior blood transfusions and/or the use of homograft material in the palliative surgeries, patients can develop preformed antibodies to donor human leukocyte antigens. This can increase the risk of graft rejection and vasculopathy post-transplant. (See  <a class="medical medical_review" href="/z/d/html/3528.html" rel="external">"Heart transplantation in adults: Indications and contraindications"</a> and  <a class="medical medical_review" href="/z/d/html/3523.html" rel="external">"Heart transplantation in adults: Prognosis"</a> and  <a class="medical medical_review" href="/z/d/html/4585.html" rel="external">"Liver transplantation in adults: Patient selection and pretransplantation evaluation"</a>.)</p><p>Because of these many comorbidities, mortality on the heart transplant waiting list is higher for Fontan patients compared with most other diagnoses. Risk factors for death on the transplant waiting list for all patients include a diagnosis of congenital heart disease (specifically hypoplastic left heart syndrome), being on extracorporeal membrane oxygenation (ECMO) or ventilator support, and a history of dialysis [<a href="#rid35">35-37</a>].</p><p>Accepted indications for heart transplant in patients after Fontan operation include:</p><p class="bulletIndent1"><span class="glyph">●</span>Ventricular systolic or diastolic dysfunction with class III or IV symptoms</p><p class="bulletIndent1"><span class="glyph">●</span>PLE</p><p class="bulletIndent1"><span class="glyph">●</span>Plastic bronchitis</p><p class="bulletIndent1"><span class="glyph">●</span>Cyanosis with associated decline in functional status</p><p class="bulletIndent1"><span class="glyph">●</span>Refractory arrhythmias in a patient who is not a candidate for Fontan conversion in conjunction with arrhythmia surgery</p><p></p><p>Recommended personnel for cardiac transplantation evaluation and management in adult Fontan patients are not well established. Some centers have all of these patients receiving transplants through the pediatric program, while others perform these transplants at adult centers with the assistance of adult congenital heart disease experts.</p><p>For Fontan patients undergoing cardiac transplantation, the in-hospital mortality remains higher than patients with other diagnoses, primarily related to preoperative risk factors discussed above (although this varies by center due to selection bias) and late referral in many cases [<a href="#rid36">36,38,39</a>]. Studies comparing longer-term mortality rates post-transplant in Fontan patients with other congenital heart disease patients have yielded mixed results. A study of 488 patients (mean age 14.8 years, range 6 months to 62 years) transplanted for congenital heart disease found that Fontan patients faced higher mortality rates at one and five years compared with non-Fontan patients (29 versus 17 percent and 40 versus 26 percent). In contrast, a meta-analysis of 351 Fontan patients (mean age 14 years, range 7 to 24 years) undergoing cardiac transplantation reported a one-year mortality rate of 20.7 percent and a five-year mortality rate of 28.8 percent, results similar to other patients with congenital heart disease [<a href="#rid40">40</a>]. Notably, studies have reported improved posttransplant survival of Fontan patients in the last 10 years compared with the prior era [<a href="#rid41">41</a>].</p><p>In general, patients transplanted for congenital disease (or undergoing retransplantation) have higher early mortality rates compared with patients transplanted for cardiomyopathy [<a href="#rid42">42</a>]. However, patients with congenital heart disease able to survive the early post-transplant period have the highest conditional survival and overall survival beyond 5 to 10 years [<a href="#rid42">42</a>]. Importantly, both PLE and plastic bronchitis appear to resolve within three to six months after transplant in most patients. (See  <a class="medical medical_review" href="/z/d/html/3528.html" rel="external">"Heart transplantation in adults: Indications and contraindications"</a> and  <a class="medical medical_review" href="/z/d/html/3523.html" rel="external">"Heart transplantation in adults: Prognosis"</a>.)</p><p>Some patients with Fontan palliation and multiple comorbid conditions are considered for multiorgan transplantation. These procedures are performed at only a few centers worldwide due to the complexity of the procedure and preoperative and postoperative care.</p><p class="headingAnchor" id="H13723678"><span class="h2">Atrioventricular valve regurgitation</span><span class="headingEndMark"> — </span>Moderate or greater AV valve regurgitation is common in patients with Fontan circulation. In a series of 1199 Fontan patients, the cumulative incidence of AV valve failure (eg, development of moderate or greater regurgitation or need for valve repair or replacement) at age 25 years was 56 percent for patients with common AV valve, 46 percent for those with single tricuspid valve, 8 percent for those with single mitral valve, and 26 percent for those with two AV valves. [<a href="#rid43">43</a>]. AV valve failure occurred both pre- or post-Fontan.</p><p>Patients with prior Fontan operation and AV valve regurgitation may be asymptomatic or present with progressive dyspnea, ventricular dilation, ventricular dysfunction, or arrhythmias. AV valve regurgitation may be caused by structural valve abnormalities (particularly of the tricuspid valve), ventricular and/or annular dilation, or impaired ventricular systolic function [<a href="#rid1">1</a>]. Moderate or greater AV valve regurgitation is a risk factor for increased long-term mortality in patients with Fontan circulation [<a href="#rid1">1</a>]. Fontan failure (defined as death, heart transplantation, Fontan takedown, Fontan conversion, plastic bronchitis, PLE, or NYHA functional class III or IV) is twice as frequent among those with AV valve failure compared with those without valve failure (23 versus 9 percent at 10 years post-Fontan and 46 percent versus 23 percent at 20 years) [<a href="#rid43">43</a>].</p><p>Annual echocardiographic imaging is recommended to assess ventricular size/function and valve function in all patients following Fontan operation.</p><p>Medical management of Fontan patients with AV valve regurgitation may include afterload reduction and diuretic therapy. Diuretics may be beneficial for Fontan patients with features of volume overload, but these agents should be used with caution since they can cause excessive fall in preload with decreased cardiac output. Afterload reduction therapy is often used in patients with single ventricle, but there are no prospective data to support the use of these agents to treat ventricular dysfunction or AV valve regurgitation in patients with Fontan circulation.</p><p>Patients with Fontan circulation, severe AV valve regurgitation and symptoms, progressive ventricular dilation, or ventricular dysfunction are evaluated for surgical valve repair or replacement. However, these patients face high risks of operative mortality, recurrent regurgitation following valve repair, and persistent ventricular dysfunction after valve repair or replacement [<a href="#rid44">44</a>]. Observational data on AV valve surgery in Fontan patients suggest that systemic mitral valve repair may be more durable than systemic tricuspid valve or common AV valve repair [<a href="#rid43">43,45</a>]. Data are lacking on the use of transcatheter interventional procedures for patients with native AV valve regurgitation following Fontan operation, with only limited case reports available [<a href="#rid46">46</a>].</p><p class="headingAnchor" id="H13723701"><span class="h2">Thrombosis</span><span class="headingEndMark"> — </span>Patients with Fontan circulation are at risk for systemic and pulmonary thromboembolic events given low flow in the Fontan circuit and associated alterations in levels of clotting and fibrinolysis factors. The reported prevalence ranges from 2 to 33 percent (overall 11 percent), depending on the mode of detection [<a href="#rid47">47,48</a>]. The risk of stroke is approximately 0.3 to 0.5 percent per year. Systemic thromboembolic events occur with greater frequency in patients with fenestrations (communication between right atrium/Fontan connection and left atrium). Pulmonary thromboembolic events can reduce cardiac output due to increases in pulmonary vascular resistance and thus can also be life threatening. (See  <a class="medical medical_review" href="/z/d/html/8253.html" rel="external">"Epidemiology and pathogenesis of acute pulmonary embolism in adults"</a> and  <a class="medical medical_review" href="/z/d/html/122375.html" rel="external">"Overview of the management and prognosis of patients with Fontan circulation", section on 'Fenestration'</a>.)</p><p>Risk factors for thrombus or low flow in the Fontan circuit include right-atrial-to-pulmonary-artery connection, Fontan connection with secondary right atrial dilation  (<a class="graphic graphic_figure graphicRef95320" href="/z/d/graphic/95320.html" rel="external">figure 1</a>), reduced cardiac output, Fontan obstruction, presence of foreign material (eg, stents), and atrial arrhythmias. In addition, some patients may have a concurrent thrombophilia (eg, protein C or protein S deficiency). By echocardiography, low flow in the Fontan circuit may appear as spontaneous echo contrast (a smoke-like pattern of blood flow), especially in patients with the right-atrial-to-pulmonary-artery connection; thrombus may also be identified incidentally on imaging assessment  (<a class="graphic graphic_diagnosticimage graphicRef95252" href="/z/d/graphic/95252.html" rel="external">image 1</a>) [<a href="#rid49">49</a>].</p><p>Thrombosis occurs not only in the right heart but also may occur in the left atrium and pulmonary veins. Transthoracic echocardiography lacks the sensitivity of transesophageal echocardiography (TEE) for intracardiac thrombus identification, so TEE is recommended to assess for thrombus in a patient presenting with systemic thromboembolism following Fontan. Cardiac CT and CMR may also identify or confirm intracardiac thrombus in Fontan patients.</p><p>Management of the thromboembolic risk in Fontan patients includes anticoagulation, maintenance of sinus rhythm, and treatment of Fontan obstruction when identified. We suggest low-dose <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> (75 to 100 mg daily) for all Fontan patients [<a href="#rid50">50</a>]. For Fontan patients with a history of thromboembolism, right atrial thrombus, right atrial blood stasis, fenestration, atrial arrhythmias, or ventricular ejection fraction less than 40 percent, we suggest anticoagulation with a vitamin K antagonist or <a class="drug drug_general" data-topicid="9498" href="/z/d/drug information/9498.html" rel="external">rivaroxaban</a>. Data are lacking on the safety and efficacy of direct oral anticoagulation agents in Fontan patients [<a href="#rid18">18</a>]. If thrombus in the Fontan patient persists despite adequate anticoagulation, surgical removal and Fontan conversion are suggested. There are limited data on thrombolytic therapy for thrombus and thromboembolic complications in patients with prior Fontan operation [<a href="#rid51">51</a>].</p><p>The best therapeutic approach for preventing thromboembolism in post-Fontan patients has not been established. Limited data are available on use of vitamin K antagonist (eg, <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a>) or <a class="drug drug_general" data-topicid="9498" href="/z/d/drug information/9498.html" rel="external">rivaroxaban</a> in this setting:</p><p class="bulletIndent1"><span class="glyph">●</span>Vitamin K antagonist – A randomized trial comparing <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> (5 mg/kg/day) and <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a> (goal international normalized ratio [INR] 2 to 3) in 111 patients with Fontan circulation found that rates of thrombosis (combined clinical and subclinical) were similar in the two treatment groups (21 and 24 percent) at two years [<a href="#rid52">52</a>]. Patients treated with warfarin with subtherapeutic INR levels had higher risks of thrombosis compared with patients on warfarin with therapeutic INR levels and those on aspirin (HR 3.53, 95% CI 1.35-9.20) [<a href="#rid53">53</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9498" href="/z/d/drug information/9498.html" rel="external">Rivaroxaban</a> – The UNIVERSE Study randomly assigned 112 children to either rivaroxaban or <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> for 12 months following Fontan operation [<a href="#rid54">54</a>]. The safety profile in the two treatment groups was similar, with clinically relevant nonmajor bleeding in 6 percent of participants on rivaroxaban versus 9 percent on aspirin. The rate of thrombotic events was similar in the two groups: one participant on rivaroxaban had a pulmonary embolism (2 percent overall event rate); on aspirin, one participant had ischemic stroke and two had venous thrombosis (9 percent overall event rate). Rivaroxaban is now approved by the US Food and Drug administration for both children and adults following Fontan operation.</p><p></p><p class="headingAnchor" id="H1582182590"><span class="h2">Bleeding</span><span class="headingEndMark"> — </span>Management of bleeding complications includes evaluation for underlying cause, discontinuation of antithrombotic agents such as <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> or vitamin K antagonists, and correction of any coagulopathy or bleeding lesion (eg, esophageal varices, hemorrhoids). Little is known about the impact of bleeding complications on these patients and how they affect long-term outcomes.</p><p>Following Fontan operation, patients are also at risk for bleeding complications. A report described bleeding complications in 412 Fontan patients during long-term (mean 11.2 years) follow-up: 13 patients (3 percent) had hemoptysis, and cerebral bleeds occurred in three patients (1 percent) [<a href="#rid55">55</a>]. These bleeding events were associated with having Fontan operation later than usual and the preoperative use of medications blocking the renin-angiotensin system (eg, ACE inhibitors, ARBs).</p><p class="headingAnchor" id="H1571221030"><span class="h2">Venous insufficiency</span><span class="headingEndMark"> — </span>The prevalence of chronic venous insufficiency and venous reflux is significantly greater in the Fontan population compared with healthy controls [<a href="#rid56">56,57</a>]. Patients with venous insufficiency present with lower-extremity edema, venous varicosities, stasis changes, and venous ulcers. (See  <a class="medical medical_review" href="/z/d/html/8196.html" rel="external">"Diagnostic evaluation of lower extremity chronic venous disease"</a> and  <a class="medical medical_review" href="/z/d/html/8181.html" rel="external">"Overview of lower extremity chronic venous disease"</a>.)</p><p>Factors associated with severe chronic venous insufficiency in one series included increased numbers of catheterization procedures with groin venous access, lower-extremity itching, and deep venous thrombosis [<a href="#rid56">56</a>]. Venous reflux in Fontan patients appears to be related to single right ventricle, use of antiarrhythmic drugs, and family history of venous disease [<a href="#rid57">57</a>]. Management of chronic venous insufficiency is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/8181.html" rel="external">"Overview of lower extremity chronic venous disease"</a>.)</p><p class="headingAnchor" id="H1023663099"><span class="h1">RESPIRATORY COMPLICATIONS</span><span class="headingEndMark"> — </span>Patients post-Fontan commonly have restrictive lung disease and may develop plastic bronchitis.</p><p class="headingAnchor" id="H2409793185"><span class="h2">Restrictive lung disease</span><span class="headingEndMark"> — </span>Patients with a history of Fontan operation have been shown to have a restrictive pattern on pulmonary function testing associated with reduced exercise capacity [<a href="#rid58">58</a>], likely related to multiple sternotomies [<a href="#rid59">59</a>], and perhaps also due to concomitant scoliosis [<a href="#rid60">60</a>]. This is functionally important, and patients with reduced forced vital capacity and breathing reserve also have poorer functional capacity on cardiopulmonary exercise testing.</p><p>They also may have differences in diffusing capacity related to the manner of passive blood flow into the lungs [<a href="#rid61">61</a>]. Regular chest radiography is typically recommended for lung disease surveillance. (See  <a class="medical medical_review" href="/z/d/html/122375.html" rel="external">"Overview of the management and prognosis of patients with Fontan circulation", section on 'Follow-up recommendations'</a>.)</p><p class="headingAnchor" id="H3226864186"><span class="h2">Plastic bronchitis</span><span class="headingEndMark"> — </span>Plastic bronchitis is estimated to occur in 3 to 4 percent of patients after Fontan procedure [<a href="#rid62">62</a>] and is associated with similar risk factors as protein-losing enteropathy (PLE) [<a href="#rid63">63</a>]. In plastic bronchitis, there is formation of mucofibrinous bronchial casts, resulting in marked airway obstruction. Patients may present with wheezing before expectorating these large casts or may require urgent removal by bronchoscopy, and life-threatening events may occur in up to 40 percent of affected patients [<a href="#rid64">64</a>]. Initial management of patients with active plastic bronchitis is similar to that of PLE, including optimization of Fontan hemodynamics and ensuring there is no alternate reversible cause of elevated central venous pressure. Proposed treatment options include inhaled or systemic steroids, aerosolized mucolytics, and aerosolized fibrinolytics such as tissue plasminogen activator [<a href="#rid65">65</a>]. There are limited available data on survival; a study of 25 patients reported a median transplant-free survival of 8.3 years after diagnosis [<a href="#rid63">63</a>].</p><p>Observational studies suggest that plastic bronchitis results from intrapulmonary lymphatic overload or leakage. In a case series, retrograde lymphatic flow from the thoracic duct to the lung parenchyma was observed in patients with plastic bronchitis, and selective embolization of the culprit lymphatic vessels was followed by symptomatic improvement [<a href="#rid66">66,67</a>]. Lymphatic embolization has also been used in the setting of acute decompensation in the setting of plastic bronchitis [<a href="#rid68">68</a>]. While early evidence is very promising, long-term follow-up will be required to determine the safety and durability of the intervention.</p><p>Cardiac transplantation appears to be effective as a long-term option for treating plastic bronchitis. In a multicenter study, all patients who survived 30 days post-transplant had full resolution of their plastic bronchitis [<a href="#rid69">69</a>]. (See  <a class="medical medical_review" href="/z/d/html/3528.html" rel="external">"Heart transplantation in adults: Indications and contraindications", section on 'Congenital heart disease'</a>.)</p><p class="headingAnchor" id="H2638984268"><span class="h1">GASTROINTESTINAL COMPLICATIONS</span></p><p class="headingAnchor" id="H2017262286"><span class="h2">Protein-losing enteropathy</span><span class="headingEndMark"> — </span>Protein-losing enteropathy (PLE) has been reported to affect 3 to 18 percent of patients following Fontan operation in various series [<a href="#rid1">1,70-73</a>]. In the largest reported multicenter series, studying &gt;3000 Fontan patients and risk factors for developing PLE, an incidence of 3.7 percent was reported [<a href="#rid72">72</a>]. PLE can present weeks to years after Fontan operation, with the average reported time around 3.5 years after Fontan [<a href="#rid72">72</a>].</p><p>Commonly presenting symptoms and signs of PLE include diarrhea, peripheral edema, abdominal pain and bloating, pleural effusions, pericardial effusions, and ascites. The intestinal protein loss seen in PLE along with nutrient malabsorption lead to hypoalbuminemia, lymphopenia, hypogammaglobulinemia, coagulation abnormalities, impaired growth, and decreased bone density. Mortality after PLE diagnosis is high, with only 46 to 59 percent of PLE patients surviving for more than five years after diagnosis in the largest studies. Death can be due to heart failure, hypocalcemia, thromboembolism, arrhythmia, and infections, with sepsis as a particular risk due to chronic hypogammaglobulinemia [<a href="#rid72">72,73</a>]. (See  <a class="medical medical_review" href="/z/d/html/4769.html" rel="external">"Protein-losing gastroenteropathy"</a>.)</p><p>A multifactorial hypothesis for the development of PLE after Fontan operation has been described [<a href="#rid1">1,66,71</a>]. The primary insult is often chronic venous congestion-induced lymphatic overload and low cardiac output with poor perfusion of the gastrointestinal mucosa. Mesenteric vascular impedance is markedly increased in patients with PLE, which in combination with vascular congestion due to elevated venous pressures, results in abnormal enterocyte function [<a href="#rid74">74</a>]. PLE patients have been shown to have specific loss of heparin sulfate and syndecan-1 proteoglycans, which is felt to worsen in the presence of inflammation or elevated central venous pressure, affecting intestinal epithelial barrier function [<a href="#rid75">75</a>]. It is likely that chronic inflammation and an undefined genetic predisposition play a role in determining which patients develop PLE after Fontan [<a href="#rid71">71,72,76</a>]. It is unclear how many of the abnormal abdominal lymphatic vessels are present at birth or whether they occur as a result of Fontan and associated operations.</p><p>The gold standard for diagnosis of PLE is a combination of clinical features (eg, diarrhea, peripheral edema, abdominal pain and bloating, ascites, and pleural or pericardial effusions) combined with laboratory confirmation (eg, low albumin and increased 24-hour clearance of alpha-1-antitrypsin). Patients with no or minimal clinical symptoms of PLE who demonstrate laboratory features consistent with the diagnosis are occasionally identified. Diagnostic laboratory testing includes 24-hour stool alpha-1-antitrypsin clearance study. Random "single-sample" analysis of stool for alpha-1-antitrypsin level is not as accurate as the formal 24-hour clearance study. However, a low "single-sample" alpha-1-antitrypsin stool concentration, coupled with normal plasma protein levels, may serve as a convenient surveillance method for asymptomatic patients in whom clinical suspicion for PLE is low [<a href="#rid77">77,78</a>]. The diagnosis and evaluation of PLE are discussed further separately. (See  <a class="medical medical_review" href="/z/d/html/4769.html" rel="external">"Protein-losing gastroenteropathy", section on 'Diagnosis'</a>.)</p><p>Management of PLE generally includes comprehensive evaluation to address underlying cause(s) (as outlined below), close clinical surveillance, and individualized therapy, depending on patient characteristics and response to therapy. All of our patients undergo cardiac catheterization to exclude Fontan obstruction and define hemodynamics to guide management. Therapy is individualized but generally involves a multifaceted dietary, medical, and occasionally interventional approach (see  <a class="medical medical_review" href="/z/d/html/4769.html" rel="external">"Protein-losing gastroenteropathy", section on 'Management'</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Consultation with a gastroenterologist with knowledge of the Fontan operation. Other causes of gastrointestinal symptoms (eg, sprue) should be excluded.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Exclusion of other causes of hypoalbuminemia and reversible mechanical causes of elevated central venous pressure such as Fontan circuit obstruction (if present, consider percutaneous or surgical intervention), significant AV valve regurgitation, restrictive interatrial septum, or left ventricular outflow tract or aortic arch obstruction. Aortography should be performed to identify aortic-pulmonary collateral vessels causing increased resistance to pulmonary flow.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Optimize general management, including the following:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Minimize anemia or iron deficiency [<a href="#rid79">79</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Diet modification with caloric augmentation.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>A high protein, high medium-chain triglyceride, reduced sodium, low-fat diet is often recommended. The clinician should monitor serum markers of nutritional status such as albumin. The primary concern with this treatment is compliance, as the diet is not easy to follow.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Improve symptoms (eg, careful diuretic therapy to treat symptoms of volume overload). Examples of diuretics used include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Loop diuretic</strong> – <a class="drug drug_general" data-topicid="8482" href="/z/d/drug information/8482.html" rel="external">Furosemide</a> is commonly used in this setting to treat volume overload; pediatric dosing is 1 mg/kg by mouth twice daily; adult dosing is 20 to 80 mg by mouth once to twice daily or by intravenous infusion. <a class="drug drug_general" data-topicid="10008" href="/z/d/drug information/10008.html" rel="external">Torsemide</a>, another loop diuretic, is often used for maintenance therapy in adults. Dosing is adjusted as needed based on symptoms. The clinician will need to check serum electrolytes as the dose is titrated (eg, hypokalemia, other disturbances).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Mineralocorticoid receptor antagonist</strong> – For <a class="drug drug_general" data-topicid="9943" href="/z/d/drug information/9943.html" rel="external">spironolactone</a>, pediatric dosing is 2 to 4 mg/kg/day by mouth divided twice daily; adult dosing is 50 to 100 mg per day dosed daily or split into twice daily doses. Dosing is adjusted as needed. Serum electrolyte monitoring is similarly required (eg, hyperkalemia, other disturbances). Gynecomastia has been reported as a common side effect. If a patient develops endocrine side effects on spironolactone (eg, gynecomastia), then <a class="drug drug_general" data-topicid="8789" href="/z/d/drug information/8789.html" rel="external">eplerenone</a> is an alternative.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Albumin infusions may also be utilized to improve serum albumin, enhance diuretic effect, and improve symptoms, though these are temporary measures. Pediatric dosing is 0.5 to 1 g/kg of 25 percent albumin IV, up to adult dosing. For adult/teen dosing, we suggest 50 g of 25 percent albumin IV; repeat weekly to monthly with titration to effect (eg, symptoms, serum albumin). The primary side effects are edema and infection from repetitive access. <a class="drug drug_general" data-topicid="8482" href="/z/d/drug information/8482.html" rel="external">Furosemide</a> is often used in combination with IV albumin to help treat edema.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Improve cardiac output using:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Afterload reduction</strong> – This is accomplished with a renin-angiotensin system inhibitor (eg, angiotensin converting enzyme inhibitor or angiotensin II receptor blocker), although direct evidence of efficacy in this setting is lacking.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Fenestration</strong> – This creates a right-to-left shunt and "off-loads" Fontan circulation [<a href="#rid11">11</a>]. The benefits and risks of fenestration are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/122375.html" rel="external">"Overview of the management and prognosis of patients with Fontan circulation", section on 'Fenestration'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Pacing</strong> – If indications for a pacemaker are present, this should be performed while preserving AV synchrony when feasible. The primary risks involved are related to the procedure itself (often epicardial) and the risk of lead or generator complications.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Reduce pulmonary arteriolar resistance</strong> using pulmonary vasodilator.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Sildenafil</strong> – The pediatric dosing is 0.5 to 1 mg/kg/dose by mouth three times daily up to the adult dose of 20 mg by mouth three times daily. The primary side effect concerns are hypotension and priapism. Other phosphodiesterase type 5 inhibitors may be used.</p><p></p><p class="bulletIndent3">For children weighing 8 to 20 kg, a typical dose is 10 mg three times daily; for those weighing over 20 kg, 20 mg three times daily. For children weighing less than 8 kg (including neonates), a typical starting dose of 0.5 mg/kg three times daily is generally used. This can then be increased as tolerated or to effect, up to a maximum of 2 mg/kg/dose every six hours [<a href="#rid80">80</a>].</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Bosentan</strong> –<strong> </strong>For infants and children &lt;12 years, the initial dose is 1 mg/kg/dose twice daily, titrated to a target dose of 2 mg/kg/dose twice daily; the maximum dose is 125 mg/dose.</p><p></p><p class="bulletIndent3">For children ≥12 years and &gt;20 to 40 kg, the initial dose is 31.25 mg twice daily, titrated to a target dose of 62.5 mg twice daily.</p><p></p><p class="bulletIndent3">Children ≥12 years and &gt;40 kg are dosed as adults.</p><p></p><p class="bulletIndent3">For adults, the initial dose is 62.5 mg twice daily; if the patient weighs ≥40 kg, this is titrated up to 125 mg twice daily.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Reduce gastrointestinal protein loss. (See  <a class="medical medical_review" href="/z/d/html/4769.html" rel="external">"Protein-losing gastroenteropathy", section on 'Management'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Case reports have described resolution of PLE with heparin therapy [<a href="#rid81">81,82</a>]. An observational study found that heparin therapy led to subjective improvement in PLE symptoms but did not increase the rate of PLE remission [<a href="#rid83">83</a>]. <a class="drug drug_general" data-topicid="8518" href="/z/d/drug information/8518.html" rel="external">Unfractionated heparin</a> (UFH) is the preferred form (low molecular weight heparin has been reported on in very limited case reports but may not be as effective) [<a href="#rid81">81-83</a>]. Pediatric dosing for UFH is 100 units/kg subcutaneously daily, up to adult dosing of 5000 units subcutaneously daily, with adjustments as needed, guided by anti-Xa assay. Side effects are bleeding and issues related to chronic injections.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Limited case reports have described using <a class="drug drug_general" data-topicid="9714" href="/z/d/drug information/9714.html" rel="external">octreotide</a> to reduce gastrointestinal protein loss [<a href="#rid84">84</a>]. When used, it is given as a three-times-daily subcutaneous injection or as a monthly intramuscular depot injection. Pediatric dosing is 1 to 10 mcg/kg/day to start, up to adult dosing of 150 mcg subcutaneously three times daily or 20 mg monthly intramuscular depot injection. If any new abdominal pain occurs on octreotide, cholelithiasis needs to be ruled out.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Observational studies suggest that oral glucocorticoid therapy (eg, <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> or <a class="drug drug_general" data-topicid="9167" href="/z/d/drug information/9167.html" rel="external">budesonide</a>) may reduce gastrointestinal protein loss in patients post-Fontan with PLE, but systemic side effects can limit treatment. Patients with liver disease are particularly intolerant of budesonide [<a href="#rid85">85</a>].</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Prednisone</strong> – Pediatric dosing is 1 to 2 mg/kg/day by mouth; adult dosing is 5 to 60 mg/day by mouth initially. Dosing is adjusted for effect and tolerance. Primary side effects include hyperglycemia, hypertension, adrenal suppression, and osteopenia.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Budesonide</strong> – Dosing (adult and pediatric) is 6 to 9 mg/day by mouth, increased by increments of 3 mg. Primary side effects include hepatotoxicity, hyperglycemia, hypertension, and adrenal suppression. Systemic steroid side effects of <a class="drug drug_general" data-topicid="9167" href="/z/d/drug information/9167.html" rel="external">budesonide</a> may be increased in the presence of significant liver disease and portosystemic shunts as the first-pass effect of the liver is diminished.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Evidence continues to suggest that abnormal hepatic lymphatic vessels are present in patients with PLE and may be the cause of much of the protein loss. Thus, targeting these vessels via selective embolization is an attractive therapeutic target [<a href="#rid66">66,67,86</a>]. The optimal timing and long-term outcomes of this intervention remain unclear, but isolated case reports suggest resolution of some of the complications related to PLE in treated patients.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>PLE is considered an indication for cardiac transplantation post-Fontan. (See <a class="local">'Management of advanced heart failure'</a> above and  <a class="medical medical_review" href="/z/d/html/3528.html" rel="external">"Heart transplantation in adults: Indications and contraindications", section on 'Congenital heart disease'</a>.)</p><p></p><p class="headingAnchor" id="H1530292940"><span class="h2">Liver disease</span><span class="headingEndMark"> — </span>Patients post-Fontan are at risk for liver disease (known as Fontan-associated liver disease), although evidence on its incidence is limited.</p><p>A retrospective multi-institution study from Japan included 1117 individuals who underwent their first Fontan operation at a median age of 3.4 years [<a href="#rid87">87</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>The incidences of liver fibrosis and focal nodular hyperplasia started to increase at five years, liver cirrhosis at 10 years, and hepatocellular carcinoma at 15 years post-Fontan operation. At 20 years after Fontan operation, the cumulative incidence of liver fibrosis was 27.3 percent, focal nodular hyperplasia was 8.7 percent, liver cirrhosis was 13 percent, and hepatocellular carcinoma was 1 percent. A total of seven patients developed hepatocellular carcinoma in this cohort. A diagnosis of either cirrhosis or hepatocellular carcinoma was associated with a five-year mortality rate of 23.6 percent.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Independent predictors for liver cirrhosis or hepatocellular carcinoma included high central venous pressure (hazard ratio [HR] 1.28 per 3 mmHg; 95% CI 1.01-1.63) and severe atrioventricular valve regurgitation (HR 6.02, 95% CI 1.53-23.77) at the postoperative cardiac catheterization (at a median of one year after Fontan operation).</p><p></p><p>After a patient has a Fontan procedure, the liver is subjected to a chronic low-cardiac output state combined with increased mesenteric resistance and chronic venous congestion [<a href="#rid71">71,74,88</a>].<strong> </strong>As a substantial amount of blood flow to the liver is dependent on the mesenteric circulation, the elevated central venous pressure and mesenteric resistance seen in Fontan patients may result in further abnormalities of blood supply to the liver [<a href="#rid88">88</a>].</p><p>Patients post-Fontan with liver fibrosis or cirrhosis are most often asymptomatic, with abnormalities found on screening blood work such as elevated liver enzymes, reduced platelet count, or radiologic abnormalities on liver ultrasound, magnetic resonance imaging (MRI), or CT. Serum liver enzymes (with progressive increase, particularly of gamma-glutamyl transpeptidase) and serum bilirubin levels are commonly elevated. Variable degrees of hepatomegaly, hepatic congestion, liver fibrosis, and cirrhosis are seen. The degree of cirrhosis is often heterogeneous and patchy within the liver. Most concerning is the increased risk of hepatocellular carcinoma in Fontan patients, particularly those with cardiac cirrhosis [<a href="#rid89">89</a>].</p><p>Patients with Fontan circulation should be advised to avoid hepatotoxins given the potential risk of liver disease. Routine liver surveillance is advised, particularly given the risk of hepatocellular carcinoma. The most effective method and frequency of surveillance for liver disease in Fontan patients are uncertain. We suggest routine liver imaging (eg, ultrasound, MRI, or CT) every three to five years in asymptomatic patients who are five or more years out from their Fontan operation. Patients with features of fibrosis or cirrhosis require close monitoring, including twice-annual laboratory surveillance (alpha-fetoprotein level) and annual imaging due to an increased risk of developing hepatocellular carcinoma. MRI and CT offer superior sensitivity for detection of hepatocellular carcinoma compared with ultrasound. Magnetic resonance elastography or ultrasound-based elastography of the liver appear promising for the noninvasive screening of patients after Fontan procedure for liver pathology; however, further research is required before these become the standard screening tools [<a href="#rid90">90-92</a>]. Routine laboratory markers such as liver enzymes are rarely helpful for screening this cohort of patients since blood tests do not adequately distinguish patients with normal, noncirrhotic changes from cirrhosis [<a href="#rid93">93,94</a>]. (See  <a class="medical medical_review" href="/z/d/html/3597.html" rel="external">"Clinical features and diagnosis of hepatocellular carcinoma", section on 'Imaging'</a>.)</p><p>Routine liver biopsy has been proposed for all patients 10 years after Fontan operation to establish the degree of liver fibrosis/cirrhosis [<a href="#rid88">88</a>]. However, the sensitivity of liver biopsy in these patients with heterogeneous liver findings is unclear, as is the availability of treatment modifications based on results. In the event of a liver mass on ultrasound, MRI, or CT, however, biopsy remains the gold standard to investigate a specific lesion for possible malignancy, as radiologic features of HCC are not pathognomonic.</p><p>Consultation with a hepatologist who has experience in hepatocardiac disorders and patients with Fontan operation is recommended for those with evidence of liver disease. Noncardiac causes of cirrhosis (eg, viral hepatitis, inherited, or autoimmune disorders) should be excluded. Patients with cirrhosis should be referred for upper endoscopy to identify esophageal varices. Prognostic stratification can be performed by assessing patients for features of portal hypertension using modifications of current criteria such as MELD-XI score [<a href="#rid95">95,96</a>]. (See  <a class="medical medical_review" href="/z/d/html/1253.html" rel="external">"Cirrhosis in adults: Etiologies, clinical manifestations, and diagnosis", section on 'Diagnosis'</a> and  <a class="medical medical_review" href="/z/d/html/1245.html" rel="external">"Primary prevention of bleeding from esophageal varices in patients with cirrhosis", section on 'Endoscopic evaluation'</a>.)</p><p class="headingAnchor" id="H3011399093"><span class="h1">RENAL COMPLICATIONS</span><span class="headingEndMark"> — </span>Patients with Fontan circulation are at risk for developing reduced glomerular filtration rate, proteinuria, and albuminuria, which may reflect end-organ dysfunction caused by low cardiac output and venous congestion [<a href="#rid1">1,97</a>]. Renal dysfunction has been observed longitudinally in at least 10 percent of children with Fontan circulation, with increasing prevalence in adolescence and adulthood [<a href="#rid1">1</a>]. Renal resistive index has emerged as a powerful predictor of late outcomes [<a href="#rid98">98</a>]. Patients who suffer acute kidney injury (AKI) at the time of Fontan operation are at higher risk of both late renal dysfunction and all-cause mortality [<a href="#rid99">99</a>].</p><p>Consultation with a nephrologist who is familiar with the Fontan operation is suggested for patients post-Fontan with evidence of kidney disease. Evaluation should include exclusion of treatable renal inflow or outflow obstruction. Cyanosis and hypotension appear to adversely impact renal function.</p><p>Management includes surveillance for kidney disease (particularly prior to any procedures) and renal protective measures including control of blood pressure (eg, treatment of hypertension and avoidance of hypotension, control of blood sugar, and counseling the patient to stay hydrated, avoid smoking, limit sodium intake, and avoid overweight/obesity) [<a href="#rid1">1</a>]. Patients with chronic kidney disease should avoid or minimize use of nephrotoxins, including nonsteroidal antiinflammatory drugs and radiographic contrast dye. (See  <a class="medical medical_review" href="/z/d/html/7172.html" rel="external">"Overview of the management of chronic kidney disease in adults"</a> and  <a class="medical medical_review" href="/z/d/html/7178.html" rel="external">"Dietary recommendations for patients with nondialysis chronic kidney disease"</a>.)</p><p>Dialysis or ultrafiltration (ie, renal replacement therapy [RRT]) may be required for patients with Fontan operation with renal failure or volume overload that does not respond to standard therapy, either immediately following Fontan operation or over long-term follow-up. In the largest study published of patients undergoing Fontan operations, 11 percent suffered AKI, with around half requiring RRT. Both in-hospital mortality and long-term all-cause mortality were higher in patients who had AKI at the time of their Fontan operation compared with those who did not have AKI.</p><p>RRT was needed in &lt;4 percent of patients following Fontan conversion at one experienced center [<a href="#rid8">8</a>]. In another surgical series, 4 of 23 consecutive patients required RRT after Fontan revision with total cavopulmonary surgery [<a href="#rid100">100</a>]. Three of the four patients treated with RRT died at a median of three months; thus, RRT requirement portends a higher mortality risk after Fontan revision or conversion. There are limited data on the outcome of patients that require chronic RRT related to progressive decline in renal function late after Fontan procedure.</p><p class="headingAnchor" id="H1639225136"><span class="h1">SOMATIC GROWTH ISSUES</span></p><p class="headingAnchor" id="H1035845423"><span class="h2">Impaired physical development</span><span class="headingEndMark"> — </span>Patients with Fontan circulation tend to have short stature, and deficits in height are associated with reduced functional health status [<a href="#rid1">1,101</a>]. Measures to prevent or treat short stature in this population have not been established. Optimizing treatment of heart failure has been proposed as one possible means of reducing the risk of short stature [<a href="#rid1">1</a>].</p><p>Many patients with Fontan circulation have decreased vitamin D levels, increased levels of parathyroid hormone, low lean muscle mass, and decreased cortical bone mineral density [<a href="#rid1">1</a>]. Heart failure may be a factor in impaired growth as suggested by an observed inverse relationship between B-type natriuretic peptide level (a marker of heart failure) and mediators of growth hormone insulin-like growth factor 1 (IGF-1) and insulin-like growth factor binding protein 3 (IGFBP-3) in children and young adults with Fontan circulation [<a href="#rid102">102</a>]. The diagnostic approach to children and adolescents with short stature is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/5834.html" rel="external">"Diagnostic approach to children and adolescents with short stature"</a> and  <a class="medical medical_review" href="/z/d/html/5832.html" rel="external">"Causes of short stature"</a>.)</p><p>In some patients, growth hormone therapy may be used to treat short stature, depending on bone age and other clinical features. This should only be done under the guidance of an endocrinologist with experience in treating patients with complex congenital heart disease.</p><p class="headingAnchor" id="H1843577165"><span class="h2">Obesity</span><span class="headingEndMark"> — </span>Avoidance of obesity is an important component of management of patients with Fontan circulation since obesity increases the risk of some complications [<a href="#rid1">1</a>]. Evidence suggests that a body mass index &lt;25 kg/m<sup>2</sup> may be optimal for cardiovascular health in the general population [<a href="#rid103">103</a>], and this target may also be helpful for patients with Fontan circulation [<a href="#rid1">1</a>]. Obesity and overweight are highly prevalent in patients with Fontan circulation, similar to the general population, but obesity poses particularly hazardous effects in patients with Fontan circulation [<a href="#rid1">1</a>]. At the time of Fontan surgery, an estimated 10 percent of patients are overweight or obese, increasing to 20 to 30 percent by 12 years of age and 38 to 50 percent in adults [<a href="#rid1">1</a>]. Recommendations for exercise are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/5371.html" rel="external">"Obesity in adults: Overview of management"</a> and  <a class="medical medical_review" href="/z/d/html/5364.html" rel="external">"Healthy diet in adults"</a> and  <a class="medical medical_review" href="/z/d/html/122375.html" rel="external">"Overview of the management and prognosis of patients with Fontan circulation", section on 'Exercise'</a>.)</p><p>Risks associated with obesity include heart failure, nonalcoholic liver disease, obstructive sleep apnea, and increased risk of cancer including hepatocellular carcinoma. (See <a class="local">'Heart failure'</a> above and <a class="local">'Liver disease'</a> above.)</p><p class="headingAnchor" id="H1555043590"><span class="h1">NEUROLOGIC COMPLICATIONS</span><span class="headingEndMark"> — </span>Patients with congenital heart disease are at increased risk of neurodevelopmental disorders, disabilities, developmental delay [<a href="#rid104">104</a>],<strong> </strong>and abnormalities in executive function.<strong> </strong>Following Fontan operation, functional and developmental status can range from normal to severely limited. Limitations may be due to genetic or developmental issues and perioperative or postoperative insults (including hypoxic-ischemic injury, macroemboli, and microemboli) [<a href="#rid1">1</a>].<strong> </strong>Since individuals with Fontan circulation have a prothrombotic state and are at risk for developing atrial arrhythmias, they are at increased risk for embolic complications, including stroke. Brain MRI studies have demonstrated widespread abnormalities in white and gray matter [<a href="#rid1">1,105</a>].</p><p>Early neurodevelopmental and neuropsychiatric evaluations of children with Fontan circulation are warranted to identify those who may benefit from targeted intervention [<a href="#rid1">1</a>]. Developmental limitations warrant genetic and neurologic assessment to identify and address treatable causes.</p><p class="headingAnchor" id="H1552723274"><span class="h1">PSYCHIATRIC DISORDERS</span><span class="headingEndMark"> — </span>In one study comparing 156 adolescents after Fontan operation with 111 healthy controls, the Fontan patients had a higher rate of any lifetime psychiatric diagnosis (65 versus 22 percent) [<a href="#rid106">106</a>]. Fontan patients also had higher rates of any lifetime anxiety disorder or adult deficit/hyperactivity disorder and scored lower on the Children's Global Assessment scale, a common measure of psychosocial function. Concerns for any psychiatric illness in a Fontan patient warrant full assessment by psychology or psychiatry specialists. Social work support is beneficial for many Fontan patients and their families and caregivers.</p><p class="headingAnchor" id="H1847140084"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/122280.html" rel="external">"Society guideline links: Congenital heart disease in adults"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/112260.html" rel="external">"Society guideline links: Arrhythmias in adults"</a>.)</p><p class="headingAnchor" id="H3043826"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>Complications in patients with Fontan circulation include cyanosis, arrhythmias, heart failure, atrioventricular valve regurgitation, thrombosis, venous insufficiency, lung disease, protein-losing enteropathy (PLE), liver disease, kidney disease, somatic growth disorders, neurologic complications, and psychiatric disorders. (See <a class="local">'Cardiovascular complications'</a> above and <a class="local">'Respiratory complications'</a> above and <a class="local">'Gastrointestinal complications'</a> above and <a class="local">'Renal complications'</a> above and <a class="local">'Somatic growth issues'</a> above and <a class="local">'Neurologic complications'</a> above and <a class="local">'Psychiatric disorders'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Conversion from atriopulmonary Fontan to an extracardiac conduit is considered in selected patients with symptomatic refractory arrhythmias, Fontan pathway obstruction, or marked exercise intolerance attributed to abnormal Fontan flow. (See <a class="local">'Indications for reintervention'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with Fontan circulation generally have mild systemic arterial oxygen desaturation (oxygen saturation most commonly 90 to 95 percent), but some patients have more marked arterial oxygen desaturation. Cyanotic Fontan patients (with oxygen saturation &lt;90 percent at rest) who have not received intentional fenestration should undergo cardiac catheterization by a congenital cardiologist, including a search for systemic-venous-to-pulmonary-venous connection via venous collateral decompression, inadvertent fenestration, pulmonary arteriovenous malformations, and other potential right-to-left shunts (eg, atrial shunt, or inferior cava, superior cava, or innominate-vein-to-left-atrial shunt). (See <a class="local">'Cyanosis and shunts'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with atrial or ventricular arrhythmias following Fontan operation require consultation with an experienced congenital heart disease electrophysiologist and urgent and aggressive management given the risk of significant morbidity, including intracardiac thrombus and heart failure. (See <a class="local">'Arrhythmias'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>All patients with Fontan circulation have chronic heart failure with elevated systemic venous pressure and low cardiac output. Additional conditions that contribute to heart failure in some Fontan patients include systemic ventricular systolic and/or diastolic dysfunction, atrioventricular valve regurgitation, rhythm disorders, volume-loading shunts, and Fontan obstruction. The management of heart failure in Fontan patients includes medical therapy for heart failure, selective use of biventricular pacing, and selective use of pulmonary vasodilator therapy. (See <a class="local">'Heart failure'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For Fontan patients with indexed pulmonary vascular resistance &gt;2 Wood units x m<sup>2</sup>, we suggest pulmonary vasodilator therapy (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Agents commonly used in this setting include an endothelin receptor antagonist (eg, <a class="drug drug_general" data-topicid="9254" href="/z/d/drug information/9254.html" rel="external">bosentan</a>) or a phosphodiesterase type 5 inhibitor (eg, <a class="drug drug_general" data-topicid="9643" href="/z/d/drug information/9643.html" rel="external">sildenafil</a>). (See <a class="local">'Pulmonary vasodilator therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Management of thromboembolic risk in Fontan patients includes anticoagulation, maintenance of sinus rhythm, and recognition/treatment of Fontan obstruction. For all Fontan patients, we recommend antithrombotic therapy (<a class="grade" href="https:///uptodate/show/grade_2" rel="external">Grade 1B</a>). The choice of antithrombotic therapy depends on the risk of thromboembolic complications. For patients at high risk (eg, cyanosis related to fenestration or collateral formation, atrial thrombus, right atrial blood stasis, fenestration, atrial arrhythmias, venovenous collaterals, ventricular ejection fraction less than 40 percent, or history of thromboembolism), we suggest anticoagulation (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). In this setting, anticoagulation options are vitamin K antagonist (eg, <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a>) or <a class="drug drug_general" data-topicid="9498" href="/z/d/drug information/9498.html" rel="external">rivaroxaban</a> (approved by the US Food and Drug Administration for this indication). For Fontan patients not at high risk of thromboembolism, low-dose <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> (75 to 100 mg daily) is sufficient. (See <a class="local">'Thrombosis'</a> above and <a class="local">'Cyanosis and shunts'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>PLE can present weeks to years after Fontan procedure. Five-year survival after PLE diagnosis is around 50 percent. Management includes exclusion of reversible mechanical causes of elevated central venous pressure, medical therapy, and in select cases catheter-based or surgical intervention, including heart transplantation. (See <a class="local">'Protein-losing enteropathy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients post-Fontan are at risk for liver disease, although the overall incidence is unknown. The most effective method of surveillance for liver disease in Fontan patients is uncertain. We suggest liver imaging (eg, magnetic resonance imaging or computed tomography) every three to five years in patients who are five or more years out from their Fontan operation. Patients with features of cirrhosis require close monitoring due to high risk of developing hepatocellular carcinoma. (See <a class="local">'Liver disease'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Rychik J, Atz AM, Celermajer DS, et al. Evaluation and Management of the Child and Adult With Fontan Circulation: A Scientific Statement From the American Heart Association. Circulation 2019; 140:e234.</a></li><li><a class="nounderline abstract_t">Stout KK, Daniels CJ, Aboulhosn JA, et al. 2018 AHA/ACC Guideline for the Management of Adults With Congenital Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 2019; 73:e81.</a></li><li><a class="nounderline abstract_t">Fontan F, Baudet E. Surgical repair of tricuspid atresia. Thorax 1971; 26:240.</a></li><li><a class="nounderline abstract_t">Kreutzer C, Kreutzer J, Kreutzer GO. Reflections on five decades of the fontan kreutzer procedure. Front Pediatr 2013; 1:45.</a></li><li><a class="nounderline abstract_t">Driscoll DJ. Long-term results of the Fontan operation. Pediatr Cardiol 2007; 28:438.</a></li><li><a class="nounderline abstract_t">Downing TE, Allen KY, Goldberg DJ, et al. Surgical and catheter-based reinterventions are common in long-term survivors of the Fontan operation. Circ Cardiovasc Interv 2017; 10.</a></li><li><a class="nounderline abstract_t">Feinstein JA, Benson DW, Dubin AM, et al. Hypoplastic left heart syndrome: current considerations and expectations. J Am Coll Cardiol 2012; 59:S1.</a></li><li><a class="nounderline abstract_t">Mavroudis C, Deal BJ, Backer CL, et al. J. Maxwell Chamberlain Memorial Paper for congenital heart surgery. 111 Fontan conversions with arrhythmia surgery: surgical lessons and outcomes. Ann Thorac Surg 2007; 84:1457.</a></li><li><a class="nounderline abstract_t">Mavroudis C, Backer CL, Deal BJ, Johnsrude CL. Fontan conversion to cavopulmonary connection and arrhythmia circuit cryoblation. J Thorac Cardiovasc Surg 1998; 115:547.</a></li><li><a class="nounderline abstract_t">Marcelletti CF, Hanley FL, Mavroudis C, et al. Revision of previous Fontan connections to total extracardiac cavopulmonary anastomosis: A multicenter experience. J Thorac Cardiovasc Surg 2000; 119:340.</a></li><li><a class="nounderline abstract_t">Saiki H, Kuwata S, Iwamoto Y, et al. Fenestration in the Fontan circulation as a strategy for chronic cardioprotection. Heart 2019; 105:1266.</a></li><li><a class="nounderline abstract_t">Magee AG, McCrindle BW, Mawson J, et al. Systemic venous collateral development after the bidirectional cavopulmonary anastomosis. Prevalence and predictors. J Am Coll Cardiol 1998; 32:502.</a></li><li><a class="nounderline abstract_t">Weber HS. Incidence and predictors for the development of significant supradiaphragmatic decompressing venous collateral channels following creation of Fontan physiology. Cardiol Young 2001; 11:289.</a></li><li><a class="nounderline abstract_t">Poterucha JT, Johnson JN, Taggart NW, et al. Embolization of Veno-venous Collaterals after the Fontan Operation Is Associated with Decreased Survival. Congenit Heart Dis 2015; 10:E230.</a></li><li><a class="nounderline abstract_t">Lasa JJ, Glatz AC, Daga A, Shah M. Prevalence of arrhythmias late after the Fontan operation. Am J Cardiol 2014; 113:1184.</a></li><li><a class="nounderline abstract_t">d'Udekem Y, Iyengar AJ, Cochrane AD, et al. The Fontan procedure: contemporary techniques have improved long-term outcomes. Circulation 2007; 116:I157.</a></li><li><a class="nounderline abstract_t">Durongpisitkul K, Porter CJ, Cetta F, et al. Predictors of early- and late-onset supraventricular tachyarrhythmias after Fontan operation. Circulation 1998; 98:1099.</a></li><li><a class="nounderline abstract_t">Georgekutty J, Kazerouninia A, Wang Y, et al. Novel oral anticoagulant use in adult Fontan patients: A single center experience. Congenit Heart Dis 2018; 13:541.</a></li><li><a class="nounderline abstract_t">Correa R, Walsh EP, Alexander ME, et al. Transbaffle mapping and ablation for atrial tachycardias after mustard, senning, or Fontan operations. J Am Heart Assoc 2013; 2:e000325.</a></li><li><a class="nounderline abstract_t">Tsao S, Deal BJ, Backer CL, et al. Device management of arrhythmias after Fontan conversion. J Thorac Cardiovasc Surg 2009; 138:937.</a></li><li><a class="nounderline abstract_t">Kouatli AA, Garcia JA, Zellers TM, et al. Enalapril does not enhance exercise capacity in patients after Fontan procedure. Circulation 1997; 96:1507.</a></li><li><a class="nounderline abstract_t">Sojak V, Mazic U, Cesen M, et al. Cardiac resynchronization therapy for the failing Fontan patient. Ann Thorac Surg 2008; 85:2136.</a></li><li><a class="nounderline abstract_t">Udink Ten Cate FEA, Germund I, Goossens SS, et al. Successful biventricular cardiac resynchronization therapy in a failing Fontan patient: Implications of ventriculo-ventricular interdependency in single ventricle physiology. Echocardiography 2019; 36:1211.</a></li><li><a class="nounderline abstract_t">Brida M, Diller GP, Gatzoulis MA. Systemic right ventricle in adults with congenital heart disease: Anatomic and phenotypic spectrum and current approach to management. Circulation 2018; 137:508.</a></li><li><a class="nounderline abstract_t">Egbe AC, Connolly HM, Miranda WR, et al. Hemodynamics of Fontan failure: The role of pulmonary vascular disease. Circ Heart Fail 2017; 10.</a></li><li><a class="nounderline abstract_t">Hebert A, Mikkelsen UR, Thilen U, et al. Bosentan improves exercise capacity in adolescents and adults after Fontan operation: the TEMPO (Treatment With Endothelin Receptor Antagonist in Fontan Patients, a Randomized, Placebo-Controlled, Double-Blind Study Measuring Peak Oxygen Consumption) study. Circulation 2014; 130:2021.</a></li><li><a class="nounderline abstract_t">Agnoletti G, Gala S, Ferroni F, et al. Endothelin inhibitors lower pulmonary vascular resistance and improve functional capacity in patients with Fontan circulation. J Thorac Cardiovasc Surg 2017; 153:1468.</a></li><li><a class="nounderline abstract_t">Goldberg DJ, French B, McBride MG, et al. Impact of oral sildenafil on exercise performance in children and young adults after the fontan operation: a randomized, double-blind, placebo-controlled, crossover trial. Circulation 2011; 123:1185.</a></li><li><a class="nounderline abstract_t">Sabri MR, Zolfi-Gol A, Ahmadi A, Haghjooy-Javanmard S. Effect of Tadalafil on Myocardial and Endothelial Function and Exercise Performance After Modified Fontan Operation. Pediatr Cardiol 2016; 37:55.</a></li><li><a class="nounderline abstract_t">Niebler RA, Ghanayem NS, Shah TK, et al. Use of a HeartWare ventricular assist device in a patient with failed Fontan circulation. Ann Thorac Surg 2014; 97:e115.</a></li><li><a class="nounderline abstract_t">Rungan S, Finucane K, Gentles T, et al. Heart transplantation in pediatric and congenital heart disease: a single-center experience. World J Pediatr Congenit Heart Surg 2014; 5:200.</a></li><li><a class="nounderline abstract_t">Newcomb AE, Negri JC, Brizard CP, d'Udekem Y. Successful left ventricular assist device bridge to transplantation after failure of a fontan revision. J Heart Lung Transplant 2006; 25:365.</a></li><li><a class="nounderline abstract_t">Durham LA 3rd, Dearani JA, Burkhart HM, et al. Application of computer modeling in systemic VAD support of failing Fontan physiology. World J Pediatr Congenit Heart Surg 2011; 2:243.</a></li><li><a class="nounderline abstract_t">Cedars A, Kutty S, Danford D, et al. Systemic ventricular assist device support in Fontan patients: A report by ACTION. J Heart Lung Transplant 2021; 40:368.</a></li><li><a class="nounderline abstract_t">Almond CS, Thiagarajan RR, Piercey GE, et al. Waiting list mortality among children listed for heart transplantation in the United States. Circulation 2009; 119:717.</a></li><li><a class="nounderline abstract_t">Bernstein D, Naftel D, Chin C, et al. Outcome of listing for cardiac transplantation for failed Fontan: a multi-institutional study. Circulation 2006; 114:273.</a></li><li><a class="nounderline abstract_t">Michielon G, Parisi F, Di Carlo D, et al. Orthotopic heart transplantation for failing single ventricle physiology. Eur J Cardiothorac Surg 2003; 24:502.</a></li><li><a class="nounderline abstract_t">Kanter KR, Mahle WT, Vincent RN, et al. Heart transplantation in children with a Fontan procedure. Ann Thorac Surg 2011; 91:823.</a></li><li><a class="nounderline abstract_t">Jayakumar KA, Addonizio LJ, Kichuk-Chrisant MR, et al. Cardiac transplantation after the Fontan or Glenn procedure. J Am Coll Cardiol 2004; 44:2065.</a></li><li><a class="nounderline abstract_t">Tabarsi N, Guan M, Simmonds J, et al. Meta-Analysis of the Effectiveness of Heart Transplantation in Patients With a Failing Fontan. Am J Cardiol 2017; 119:1269.</a></li><li><a class="nounderline abstract_t">Simpson KE, Pruitt E, Kirklin JK, et al. Fontan Patient Survival After Pediatric Heart Transplantation Has Improved in the Current Era. Ann Thorac Surg 2017; 103:1315.</a></li><li><a class="nounderline abstract_t">Lund LH, Edwards LB, Dipchand AI, et al. The Registry of the International Society for Heart and Lung Transplantation: Thirty-third Adult Heart Transplantation Report-2016; Focus Theme: Primary Diagnostic Indications for Transplant. J Heart Lung Transplant 2016; 35:1158.</a></li><li><a class="nounderline abstract_t">King G, Ayer J, Celermajer D, et al. Atrioventricular Valve Failure in Fontan Palliation. J Am Coll Cardiol 2019; 73:810.</a></li><li><a class="nounderline abstract_t">Menon SC, Dearani JA, Cetta F. Long-term outcome after atrioventricular valve surgery following modified Fontan operation. Cardiol Young 2011; 21:83.</a></li><li><a class="nounderline abstract_t">Mavroudis C, Stewart RD, Backer CL, et al. Atrioventricular valve procedures with repeat fontan operations: influence of valve pathology, ventricular function, and arrhythmias on outcome. Ann Thorac Surg 2005; 80:29.</a></li><li><a class="nounderline abstract_t">Butera G, Lucchese G, Austin C, Frigiola A. Hybrid trans-apical atrioventricular valve-in-valve implantation in Fontan circulation. Catheter Cardiovasc Interv 2020; 95:950.</a></li><li><a class="nounderline abstract_t">Egbe AC, Connolly HM, Niaz T, et al. Prevalence and outcome of thrombotic and embolic complications in adults after Fontan operation. Am Heart J 2017; 183:10.</a></li><li><a class="nounderline abstract_t">Mahnke CB, Boyle GJ, Janosky JE, et al. Anticoagulation and incidence of late cerebrovascular accidents following the Fontan procedure. Pediatr Cardiol 2005; 26:56.</a></li><li><a class="nounderline abstract_t">Tsang W, Johansson B, Salehian O, et al. Intracardiac thrombus in adults with the Fontan circulation. Cardiol Young 2007; 17:646.</a></li><li><a class="nounderline abstract_t">Iyengar AJ, Winlaw DS, Galati JC, et al. No difference between aspirin and warfarin after extracardiac Fontan in a propensity score analysis of 475 patients. Eur J Cardiothorac Surg 2016; 50:980.</a></li><li><a class="nounderline abstract_t">Kudumula V, Mathur S, Bu'Lock F. Successful thrombolysis of massive intracardiac thrombus in atriopulmonary Fontan circulation. Cardiol Young 2010; 20:443.</a></li><li><a class="nounderline abstract_t">Monagle P, Cochrane A, Roberts R, et al. A multicenter, randomized trial comparing heparin/warfarin and acetylsalicylic acid as primary thromboprophylaxis for 2 years after the Fontan procedure in children. J Am Coll Cardiol 2011; 58:645.</a></li><li><a class="nounderline abstract_t">McCrindle BW, Manlhiot C, Cochrane A, et al. Factors associated with thrombotic complications after the Fontan procedure: a secondary analysis of a multicenter, randomized trial of primary thromboprophylaxis for 2 years after the Fontan procedure. J Am Coll Cardiol 2013; 61:346.</a></li><li><a class="nounderline abstract_t">McCrindle BW, Michelson AD, Van Bergen AH, et al. Thromboprophylaxis for Children Post-Fontan Procedure: Insights From the UNIVERSE Study. J Am Heart Assoc 2021; 10:e021765.</a></li><li><a class="nounderline abstract_t">Ohuchi H, Yasuda K, Miyazaki A, et al. Prevalence and predictors of haemostatic complications in 412 Fontan patients: their relation to anticoagulation and haemodynamics. Eur J Cardiothorac Surg 2015; 47:511.</a></li><li><a class="nounderline abstract_t">Valente AM, Bhatt AB, Cook S, et al. The CALF (Congenital Heart Disease in Adults Lower Extremity Systemic Venous Health in Fontan Patients) study. J Am Coll Cardiol 2010; 56:144.</a></li><li><a class="nounderline abstract_t">Bhatt AB, Landzberg MJ, Gerhard-Herman M, et al. Pathophysiology of chronic venous insufficiency in adults with a Fontan circulation (a pre-defined substudy of the CALF investigation). Int J Cardiol 2013; 165:41.</a></li><li><a class="nounderline abstract_t">Opotowsky AR, Landzberg MJ, Earing MG, et al. Abnormal spirometry after the Fontan procedure is common and associated with impaired aerobic capacity. Am J Physiol Heart Circ Physiol 2014; 307:H110.</a></li><li><a class="nounderline abstract_t">Fredriksen PM, Therrien J, Veldtman G, et al. Lung function and aerobic capacity in adult patients following modified Fontan procedure. Heart 2001; 85:295.</a></li><li><a class="nounderline abstract_t">Kadhim M, Pizarro C, Holmes L Jr, et al. Prevalence of scoliosis in patients with Fontan circulation. Arch Dis Child 2013; 98:170.</a></li><li><a class="nounderline abstract_t">Matthews IL, Fredriksen PM, Bjørnstad PG, et al. Reduced pulmonary function in children with the Fontan circulation affects their exercise capacity. Cardiol Young 2006; 16:261.</a></li><li><a class="nounderline abstract_t">Caruthers RL, Kempa M, Loo A, et al. Demographic characteristics and estimated prevalence of Fontan-associated plastic bronchitis. Pediatr Cardiol 2013; 34:256.</a></li><li><a class="nounderline abstract_t">Schumacher KR, Singh TP, Kuebler J, et al. Risk factors and outcome of Fontan-associated plastic bronchitis: a case-control study. J Am Heart Assoc 2014; 3:e000865.</a></li><li><a class="nounderline abstract_t">Brogan TV, Finn LS, Pyskaty DJ Jr, et al. Plastic bronchitis in children: a case series and review of the medical literature. Pediatr Pulmonol 2002; 34:482.</a></li><li><a class="nounderline abstract_t">Costello JM, Steinhorn D, McColley S, et al. Treatment of plastic bronchitis in a Fontan patient with tissue plasminogen activator: a case report and review of the literature. Pediatrics 2002; 109:e67.</a></li><li><a class="nounderline abstract_t">Dori Y, Keller MS, Rychik J, Itkin M. Successful treatment of plastic bronchitis by selective lymphatic embolization in a Fontan patient. Pediatrics 2014; 134:e590.</a></li><li><a class="nounderline abstract_t">Dori Y, Keller MS, Rome JJ, et al. Percutaneous Lymphatic Embolization of Abnormal Pulmonary Lymphatic Flow as Treatment of Plastic Bronchitis in Patients With Congenital Heart Disease. Circulation 2016; 133:1160.</a></li><li><a class="nounderline abstract_t">Pieper CC, Hart C, Schneider M, et al. Transabdominal Lymphatic Embolization During Extracorporeal Membrane Oxygenation as an Urgent Treatment of Cataclysmic, Uncontrollable Plastic Bronchitis. J Vasc Interv Radiol 2021; 32:766.</a></li><li><a class="nounderline abstract_t">Gossett JG, Almond CS, Kirk R, et al. Outcomes of cardiac transplantation in single-ventricle patients with plastic bronchitis: a multicenter study. J Am Coll Cardiol 2013; 61:985.</a></li><li><a class="nounderline abstract_t">Goldberg DJ, Dodds K, Rychik J. Rare problems associated with the Fontan circulation. Cardiol Young 2010; 20 Suppl 3:113.</a></li><li><a class="nounderline abstract_t">Rychik J. Protein-losing enteropathy after Fontan operation. Congenit Heart Dis 2007; 2:288.</a></li><li><a class="nounderline abstract_t">Mertens L, Hagler DJ, Sauer U, et al. Protein-losing enteropathy after the Fontan operation: an international multicenter study. PLE study group. J Thorac Cardiovasc Surg 1998; 115:1063.</a></li><li><a class="nounderline abstract_t">Feldt RH, Driscoll DJ, Offord KP, et al. Protein-losing enteropathy after the Fontan operation. J Thorac Cardiovasc Surg 1996; 112:672.</a></li><li><a class="nounderline abstract_t">Rychik J, Gui-Yang S. Relation of mesenteric vascular resistance after Fontan operation and protein-losing enteropathy. Am J Cardiol 2002; 90:672.</a></li><li><a class="nounderline abstract_t">Bode L, Salvestrini C, Park PW, et al. Heparan sulfate and syndecan-1 are essential in maintaining murine and human intestinal epithelial barrier function. J Clin Invest 2008; 118:229.</a></li><li><a class="nounderline abstract_t">Johnson JN, Driscoll DJ, O'Leary PW. Protein-losing enteropathy and the Fontan operation. Nutr Clin Pract 2012; 27:375.</a></li><li><a class="nounderline abstract_t">Florent C, L'Hirondel C, Desmazures C, et al. Intestinal clearance of alpha 1-antitrypsin. A sensitive method for the detection of protein-losing enteropathy. Gastroenterology 1981; 81:777.</a></li><li><a class="nounderline abstract_t">Fujii T, Shimizu T, Takahashi K, et al. Fecal alpha1-antitrypsin concentrations as a measure of enteric protein loss after modified fontan operations. J Pediatr Gastroenterol Nutr 2003; 37:577.</a></li><li><a class="nounderline abstract_t">Vyas H, Driscoll DJ, Cetta F, et al. Gastrointestinal bleeding and protein-losing enteropathy after the fontan operation. Am J Cardiol 2006; 98:666.</a></li><li><a class="nounderline abstract_t">Dhariwal AK, Bavdekar SB. Sildenafil in pediatric pulmonary arterial hypertension. J Postgrad Med 2015; 61:181.</a></li><li><a class="nounderline abstract_t">Bhagirath KM, Tam JW. Resolution of protein-losing enteropathy with low-molecular weight heparin in an adult patient with Fontan palliation. Ann Thorac Surg 2007; 84:2110.</a></li><li><a class="nounderline abstract_t">Donnelly JP, Rosenthal A, Castle VP, Holmes RD. Reversal of protein-losing enteropathy with heparin therapy in three patients with univentricular hearts and Fontan palliation. J Pediatr 1997; 130:474.</a></li><li><a class="nounderline abstract_t">Ryerson L, Goldberg C, Rosenthal A, Armstrong A. Usefulness of heparin therapy in protein-losing enteropathy associated with single ventricle palliation. Am J Cardiol 2008; 101:248.</a></li><li><a class="nounderline abstract_t">John AS, Phillips SD, Driscoll DJ, et al. The use of octreotide to successfully treat protein-losing enteropathy following the Fontan operation. Congenit Heart Dis 2011; 6:653.</a></li><li><a class="nounderline abstract_t">John AS, Driscoll DJ, Warnes CA, et al. The use of oral budesonide in adolescents and adults with protein-losing enteropathy after the Fontan operation. Ann Thorac Surg 2011; 92:1451.</a></li><li><a class="nounderline abstract_t">Itkin M, Piccoli DA, Nadolski G, et al. Protein-Losing Enteropathy in Patients With Congenital Heart Disease. J Am Coll Cardiol 2017; 69:2929.</a></li><li><a class="nounderline abstract_t">Inuzuka R, Nii M, Inai K, et al. Predictors of liver cirrhosis and hepatocellular carcinoma among perioperative survivors of the Fontan operation. Heart 2023; 109:276.</a></li><li><a class="nounderline abstract_t">Rychik J, Veldtman G, Rand E, et al. The precarious state of the liver after a Fontan operation: summary of a multidisciplinary symposium. Pediatr Cardiol 2012; 33:1001.</a></li><li><a class="nounderline abstract_t">Asrani SK, Warnes CA, Kamath PS. Hepatocellular carcinoma after the Fontan procedure. N Engl J Med 2013; 368:1756.</a></li><li><a class="nounderline abstract_t">Wallihan DB, Podberesky DJ, Marino BS, et al. Relationship of MR elastography determined liver stiffness with cardiac function after Fontan palliation. J Magn Reson Imaging 2014; 40:1328.</a></li><li><a class="nounderline abstract_t">Song P, Mellema DC, Sheedy SP, et al. Performance of 2-Dimensional Ultrasound Shear Wave Elastography in Liver Fibrosis Detection Using Magnetic Resonance Elastography as the Reference Standard: A Pilot Study. J Ultrasound Med 2016; 35:401.</a></li><li><a class="nounderline abstract_t">Alsaied T, Possner M, Lubert AM, et al. Relation of Magnetic Resonance Elastography to Fontan Failure and Portal Hypertension. Am J Cardiol 2019; 124:1454.</a></li><li><a class="nounderline abstract_t">Kiesewetter CH, Sheron N, Vettukattill JJ, et al. Hepatic changes in the failing Fontan circulation. Heart 2007; 93:579.</a></li><li><a class="nounderline abstract_t">Simpson KE, Esmaeeli A, Khanna G, et al. Liver cirrhosis in Fontan patients does not affect 1-year post-heart transplant mortality or markers of liver function. J Heart Lung Transplant 2014; 33:170.</a></li><li><a class="nounderline abstract_t">Assenza GE, Graham DA, Landzberg MJ, et al. MELD-XI score and cardiac mortality or transplantation in patients after Fontan surgery. Heart 2013; 99:491.</a></li><li><a class="nounderline abstract_t">Elder RW, McCabe NM, Hebson C, et al. Features of portal hypertension are associated with major adverse events in Fontan patients: the VAST study. Int J Cardiol 2013; 168:3764.</a></li><li><a class="nounderline abstract_t">Mori M, Aguirre AJ, Elder RW, et al. Beyond a broken heart: circulatory dysfunction in the failing Fontan. Pediatr Cardiol 2014; 35:569.</a></li><li><a class="nounderline abstract_t">Ohuchi H, Negishi J, Hayama Y, et al. Renal resistive index reflects Fontan pathophysiology and predicts mortality. Heart 2017; 103:1631.</a></li><li><a class="nounderline abstract_t">Niaz T, Stephens EH, Gleich SJ, et al. Acute Kidney Injury and Renal Replacement Therapy After Fontan Operation. Am J Cardiol 2021; 161:84.</a></li><li><a class="nounderline abstract_t">Sammour F, Haw M, Paisey J, et al. Renal function of patients with a failing Fontan circuit undergoing total cavopulmonary revision surgery. Pediatr Cardiol 2009; 30:282.</a></li><li><a class="nounderline abstract_t">Cohen MS, Zak V, Atz AM, et al. Anthropometric measures after Fontan procedure: implications for suboptimal functional outcome. Am Heart J 2010; 160:1092.</a></li><li><a class="nounderline abstract_t">Avitabile CM, Leonard MB, Brodsky JL, et al. Usefulness of insulin like growth factor 1 as a marker of heart failure in children and young adults after the Fontan palliation procedure. Am J Cardiol 2015; 115:816.</a></li><li><a class="nounderline abstract_t">Khan SS, Ning H, Wilkins JT, et al. Association of Body Mass Index With Lifetime Risk of Cardiovascular Disease and Compression of Morbidity. JAMA Cardiol 2018; 3:280.</a></li><li><a class="nounderline abstract_t">Marino BS, Lipkin PH, Newburger JW, et al. Neurodevelopmental outcomes in children with congenital heart disease: evaluation and management: a scientific statement from the American Heart Association. Circulation 2012; 126:1143.</a></li><li><a class="nounderline abstract_t">Watson CG, Stopp C, Wypij D, et al. Reduced cortical volume and thickness and their relationship to medical and operative features in post-Fontan children and adolescents. Pediatr Res 2017; 81:881.</a></li><li><a class="nounderline abstract_t">DeMaso DR, Calderon J, Taylor GA, et al. Psychiatric Disorders in Adolescents With Single Ventricle Congenital Heart Disease. Pediatrics 2017; 139.</a></li></ol></div><div id="topicVersionRevision">Topic 95232 Version 25.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31256636" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Evaluation and Management of the Child and Adult With Fontan Circulation: A Scientific Statement From the American Heart Association.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30121239" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : 2018 AHA/ACC Guideline for the Management of Adults With Congenital Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5089489" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Surgical repair of tricuspid atresia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24400290" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Reflections on five decades of the fontan kreutzer procedure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17768650" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Long-term results of the Fontan operation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28851719" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Surgical and catheter-based reinterventions are common in long-term survivors of the Fontan operation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22192720" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Hypoplastic left heart syndrome: current considerations and expectations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17954046" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : J. Maxwell Chamberlain Memorial Paper for congenital heart surgery. 111 Fontan conversions with arrhythmia surgery: surgical lessons and outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9535440" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Fontan conversion to cavopulmonary connection and arrhythmia circuit cryoblation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10649210" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Revision of previous Fontan connections to total extracardiac cavopulmonary anastomosis: A multicenter experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30826770" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Fenestration in the Fontan circulation as a strategy for chronic cardioprotection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9708483" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Systemic venous collateral development after the bidirectional cavopulmonary anastomosis. Prevalence and predictors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11388623" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Incidence and predictors for the development of significant supradiaphragmatic decompressing venous collateral channels following creation of Fontan physiology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26010433" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Embolization of Veno-venous Collaterals after the Fontan Operation Is Associated with Decreased Survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24513470" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Prevalence of arrhythmias late after the Fontan operation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17846297" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : The Fontan procedure: contemporary techniques have improved long-term outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9736597" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Predictors of early- and late-onset supraventricular tachyarrhythmias after Fontan operation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29575675" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Novel oral anticoagulant use in adult Fontan patients: A single center experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24052498" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Transbaffle mapping and ablation for atrial tachycardias after mustard, senning, or Fontan operations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19660377" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Device management of arrhythmias after Fontan conversion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9315539" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Enalapril does not enhance exercise capacity in patients after Fontan procedure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18498846" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Cardiac resynchronization therapy for the failing Fontan patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31148229" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Successful biventricular cardiac resynchronization therapy in a failing Fontan patient: Implications of ventriculo-ventricular interdependency in single ventricle physiology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29378757" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Systemic right ventricle in adults with congenital heart disease: Anatomic and phenotypic spectrum and current approach to management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29246897" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Hemodynamics of Fontan failure: The role of pulmonary vascular disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25446057" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Bosentan improves exercise capacity in adolescents and adults after Fontan operation: the TEMPO (Treatment With Endothelin Receptor Antagonist in Fontan Patients, a Randomized, Placebo-Controlled, Double-Blind Study Measuring Peak Oxygen Consumption) study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28283234" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Endothelin inhibitors lower pulmonary vascular resistance and improve functional capacity in patients with Fontan circulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21382896" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Impact of oral sildenafil on exercise performance in children and young adults after the fontan operation: a randomized, double-blind, placebo-controlled, crossover trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26215768" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Effect of Tadalafil on Myocardial and Endothelial Function and Exercise Performance After Modified Fontan Operation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24694452" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Use of a HeartWare ventricular assist device in a patient with failed Fontan circulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24668964" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Heart transplantation in pediatric and congenital heart disease: a single-center experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16507435" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Successful left ventricular assist device bridge to transplantation after failure of a fontan revision.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23804979" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Application of computer modeling in systemic VAD support of failing Fontan physiology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33642140" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Systemic ventricular assist device support in Fontan patients: A report by ACTION.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19171850" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Waiting list mortality among children listed for heart transplantation in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16847155" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Outcome of listing for cardiac transplantation for failed Fontan: a multi-institutional study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14500066" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Orthotopic heart transplantation for failing single ventricle physiology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21353006" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Heart transplantation in children with a Fontan procedure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15542293" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Cardiac transplantation after the Fontan or Glenn procedure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28233535" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Meta-Analysis of the Effectiveness of Heart Transplantation in Patients With a Failing Fontan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27863728" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Fontan Patient Survival After Pediatric Heart Transplantation Has Improved in the Current Era.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27772668" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : The Registry of the International Society for Heart and Lung Transplantation: Thirty-third Adult Heart Transplantation Report-2016; Focus Theme: Primary Diagnostic Indications for Transplant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30784675" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Atrioventricular Valve Failure in Fontan Palliation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20977827" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Long-term outcome after atrioventricular valve surgery following modified Fontan operation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15975335" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Atrioventricular valve procedures with repeat fontan operations: influence of valve pathology, ventricular function, and arrhythmias on outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31912986" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Hybrid trans-apical atrioventricular valve-in-valve implantation in Fontan circulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27979032" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Prevalence and outcome of thrombotic and embolic complications in adults after Fontan operation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14994183" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Anticoagulation and incidence of late cerebrovascular accidents following the Fontan procedure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17956657" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Intracardiac thrombus in adults with the Fontan circulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27229665" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : No difference between aspirin and warfarin after extracardiac Fontan in a propensity score analysis of 475 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20590003" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Successful thrombolysis of massive intracardiac thrombus in atriopulmonary Fontan circulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21798429" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : A multicenter, randomized trial comparing heparin/warfarin and acetylsalicylic acid as primary thromboprophylaxis for 2 years after the Fontan procedure in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23246393" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Factors associated with thrombotic complications after the Fontan procedure: a secondary analysis of a multicenter, randomized trial of primary thromboprophylaxis for 2 years after the Fontan procedure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34558312" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Thromboprophylaxis for Children Post-Fontan Procedure: Insights From the UNIVERSE Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24699205" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Prevalence and predictors of haemostatic complications in 412 Fontan patients: their relation to anticoagulation and haemodynamics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20620728" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : The CALF (Congenital Heart Disease in Adults Lower Extremity Systemic Venous Health in Fontan Patients) study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21839529" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Pathophysiology of chronic venous insufficiency in adults with a Fontan circulation (a pre-defined substudy of the CALF investigation).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24791784" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Abnormal spirometry after the Fontan procedure is common and associated with impaired aerobic capacity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11179270" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Lung function and aerobic capacity in adult patients following modified Fontan procedure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23264433" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Prevalence of scoliosis in patients with Fontan circulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16725065" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Reduced pulmonary function in children with the Fontan circulation affects their exercise capacity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22797520" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Demographic characteristics and estimated prevalence of Fontan-associated plastic bronchitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24755155" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Risk factors and outcome of Fontan-associated plastic bronchitis: a case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12422347" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Plastic bronchitis in children: a case series and review of the medical literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11927740" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Treatment of plastic bronchitis in a Fontan patient with tissue plasminogen activator: a case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25002668" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Successful treatment of plastic bronchitis by selective lymphatic embolization in a Fontan patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26864093" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Percutaneous Lymphatic Embolization of Abnormal Pulmonary Lymphatic Flow as Treatment of Plastic Bronchitis in Patients With Congenital Heart Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33933253" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Transabdominal Lymphatic Embolization During Extracorporeal Membrane Oxygenation as an Urgent Treatment of Cataclysmic, Uncontrollable Plastic Bronchitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23290545" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Outcomes of cardiac transplantation in single-ventricle patients with plastic bronchitis: a multicenter study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21087567" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Rare problems associated with the Fontan circulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18377444" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Protein-losing enteropathy after Fontan operation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9605076" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Protein-losing enteropathy after the Fontan operation: an international multicenter study. PLE study group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8800155" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Protein-losing enteropathy after the Fontan operation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12231106" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Relation of mesenteric vascular resistance after Fontan operation and protein-losing enteropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18064305" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Heparan sulfate and syndecan-1 are essential in maintaining murine and human intestinal epithelial barrier function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22516942" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Protein-losing enteropathy and the Fontan operation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6973500" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Intestinal clearance of alpha 1-antitrypsin. A sensitive method for the detection of protein-losing enteropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14581800" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Fecal alpha1-antitrypsin concentrations as a measure of enteric protein loss after modified fontan operations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16923458" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Gastrointestinal bleeding and protein-losing enteropathy after the fontan operation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26119438" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Sildenafil in pediatric pulmonary arterial hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18036954" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Resolution of protein-losing enteropathy with low-molecular weight heparin in an adult patient with Fontan palliation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9063428" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Reversal of protein-losing enteropathy with heparin therapy in three patients with univentricular hearts and Fontan palliation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18178416" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Usefulness of heparin therapy in protein-losing enteropathy associated with single ventricle palliation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21545466" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : The use of octreotide to successfully treat protein-losing enteropathy following the Fontan operation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21784410" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : The use of oral budesonide in adolescents and adults with protein-losing enteropathy after the Fontan operation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28619193" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Protein-Losing Enteropathy in Patients With Congenital Heart Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35768191" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Predictors of liver cirrhosis and hepatocellular carcinoma among perioperative survivors of the Fontan operation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22534759" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : The precarious state of the liver after a Fontan operation: summary of a multidisciplinary symposium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23635071" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Hepatocellular carcinoma after the Fontan procedure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24408379" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Relationship of MR elastography determined liver stiffness with cardiac function after Fontan palliation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26782164" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Performance of 2-Dimensional Ultrasound Shear Wave Elastography in Liver Fibrosis Detection Using Magnetic Resonance Elastography as the Reference Standard: A Pilot Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31474329" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Relation of Magnetic Resonance Elastography to Fontan Failure and Portal Hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17005713" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Hepatic changes in the failing Fontan circulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24365764" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Liver cirrhosis in Fontan patients does not affect 1-year post-heart transplant mortality or markers of liver function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23406689" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : MELD-XI score and cardiac mortality or transplantation in patients after Fontan surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23849105" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Features of portal hypertension are associated with major adverse events in Fontan patients: the VAST study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24531876" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Beyond a broken heart: circulatory dysfunction in the failing Fontan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28465331" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Renal resistive index reflects Fontan pathophysiology and predicts mortality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34794622" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Acute Kidney Injury and Renal Replacement Therapy After Fontan Operation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19052801" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Renal function of patients with a failing Fontan circuit undergoing total cavopulmonary revision surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21146663" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Anthropometric measures after Fontan procedure: implications for suboptimal functional outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25616534" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Usefulness of insulin like growth factor 1 as a marker of heart failure in children and young adults after the Fontan palliation procedure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29490333" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Association of Body Mass Index With Lifetime Risk of Cardiovascular Disease and Compression of Morbidity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22851541" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Neurodevelopmental outcomes in children with congenital heart disease: evaluation and management: a scientific statement from the American Heart Association.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28157834" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Reduced cortical volume and thickness and their relationship to medical and operative features in post-Fontan children and adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28148729" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Psychiatric Disorders in Adolescents With Single Ventricle Congenital Heart Disease.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
